Buspi[INVESTIGATOR_163274] E arly Satiety and Symptoms of Gastroparesis:   
A Multicenter, Randomized, Placebo -Controlled, Double-Masked 
Trial (BESST )  
 
Protocol Number: 10   
National Clinical Trial (NCT) Identified Number:  [STUDY_ID_REMOVED]  
Principal Investigator s: Henry P. Parkman , MD  and Pankaj Jay Pasricha, MD  
IND Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)   
Funded by : [CONTACT_226543] (NIDDK)   
Version Number:  1. 3 
13 January 2022  
 
Summary of Changes from Previous Versions, v1.2 (11 Sep 2020 ): 
Affected Section(s)  Summary of Revisions Made  Rationale  
1.1 Synopsis  Changed Total Study Duration  to 137 weeks ( 31.5  months)  
Changed Recruitment to 131 weeks ( 30 months)  
Changed: Expected enrollment rate to .6 participant s per month per 
clinical center (18 participants each at 6 centers) Recruitment has been slower 
than expected. This will extend 
through February 28, [ADDRESS_272283].,  
Scottsdale, AZ [ZIP_CODE]  
[PHONE_4791]  
[EMAIL_4471]  Added new Medical Monitor  
 
  
BESST  Protocol #  [ADDRESS_272284] Protocol Version 13  ii  
 
Table of Contents  
STATEMENT OF COMPLIANCE  ............................................................................................................................ 1 
1 PROTOCOL SUMMARY  .............................................................................................................................. 1 
1.1 Synopsis  ............................................................................................................................................... 1 
1.2 Schema  ................................................................................................................................................ 6 
1.3 Schedule of Activities (SOA)  ............................................................................................................. 7 
2 INTRODUCTION  ........................................................................................................................................... 8 
2.1 Study Rationale  ................................................................................................................................... 8 
2.2 Background  .......................................................................................................................................... 9 
2.3 Risk/Benefit Assessment  ................................................................................................................. [ADDRESS_272285] treatment recommendations  ....................................................................... 19 
5.4 Screen Failures  .................................................................................................................................  19 
5.5 Strategies for Recruitment and Retention .....................................................................................  19 
5.5.1  Recruitment  .................................................................................................................... 19 
6 STUDY INTERVENTION  ............................................................................................................................ 20 
6.1 Study Intervention(s) Administration  .............................................................................................. 20 
6.1.1  Study Intervention Description From FDA Package INsert  ..................................... 20 
6.1.2  Dosing and Administration  ........................................................................................... 21 
6.2 Preparation/Handling/Storage/Accountability  ............................................................................... [ADDRESS_272286] Storage and Stability  ......................................................................................  22 
6.2.4  Preparation  ..................................................................................................................... 22 
6.3 Measures to Minimize Bias: Randomization and Blinding  .......................................................... 23 
6.4 Study Intervention Compliance  ....................................................................................................... 23 
6.5 Concomitant Therapy  ....................................................................................................................... 24 
6.5.1  Rescue Medicine  ........................................................................................................... 24 
7 STUDY INTE RVENTION DISCONTINUATION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL  25 
7.1 Discontinuation of Study Intervention  ............................................................................................ 25 
7.2 Participant Discontinuation/Withdrawal from the Study  .............................................................. [ADDRESS_272287]  Protocol #  [ADDRESS_272288] Protocol -  Version 1.3  Confidential, not for distribution  2 8 STUDY ASSESSMENTS AND PROCEDURES  .....................................................................................  26 
8.1 Efficacy Assessments  ...................................................................................................................... 26 
8.1.1  Visit schedule overview  ................................................................................................ 26 
8.1.2  Screening and baseline data collection  ..................................................................... 26 
8.1.3  Randomization visit  ....................................................................................................... 27 
8.1.4  Follow -up visits  ..............................................................................................................  28 
8.1.5  Standardized questionnaires  ....................................................................................... 28 
8.1.6  Study Procedures  .......................................................................................................... 30 
8.2 Safety and Other Assessments  ...................................................................................................... 32 
8.3 Adverse Events and Serious Adverse Events  .............................................................................. 33 
8.3.1  Definition of Adverse Events (AE)  .............................................................................. 33 
8.3.2  Definition of Serious Adverse Events (SAE)  .............................................................  [ADDRESS_272289]  ............................................................................................ 37 
8.3.9  Reporting of Pregnancy  ................................................................................................ 37 
8.4 Unanticipated Problems  ................................................................................................................... 37 
8.4.1  Definition of Unanticipated Problems (UP)  ................................................................ 37 
8.4.2  Unanticipated Problem Reporting  ............................................................................... 38 
8.4.3  Reporting Unanticipated Problems to Participants  ................................................... 38 
9 STATISTICAL CONSIDERATIONS  .......................................................................................................... 38 
9.1 Statistical Hypotheses  ...................................................................................................................... 38 
9.2 Sample Size Determination ............................................................................................................. 39 
9.3 Populations for Analyses  ................................................................................................................. 40 
9.4 Statistical Analyses  ........................................................................................................................... 40 
9.4.1  General Approach  ......................................................................................................... 40 
9.4.2  Analysis of the Primary Efficacy OUTCOME(s)  ........................................................ 40 
9.4.3  Analysis of the Secondary OUTCOME(s)  .................................................................  41 
9.4.4  Safety Analyses  ............................................................................................................. 42 
9.4.5  Baseline Descriptive Statistics  .................................................................................... 42 
9.4.6  Planned Interim Analyses  ............................................................................................ 43 
9.4.7 Sub-Group Analyses  ..................................................................................................... 43 
9.4.8  Tabulation of Individual participant Data  .................................................................... 43 
9.4.9  Exploratory Analyses  .................................................................................................... 43 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS .............................. 44 
10.1  Regulatory, Ethical, and Study Oversight Considerations  .......................................................... 44 
10.1.1  Informed Consent Process  .......................................................................................... 44 
10.1.2  Study Discontinuation and Closure  ............................................................................ 45 
10.1.3  Confidentiality and Privacy  ........................................................................................... 45 
10.1.4  Future Use of Stored Specimens and Data ............................................................... 46 
10.1.5  Key Roles and Study Governance  .............................................................................. 47 
10.1.6  Safety Oversight: Data and Safety MOnitoring BOard  ............................................ [ADDRESS_272290]  Protocol #  [ADDRESS_272291] Policy  .............................................................................................. 50 
10.2  Additional Considerations  ................................................................................................................ 50 
10.3  Abbreviations  ..................................................................................................................................... 51 
10.4  Protocol Amendment History ........................................................................................................... 53 
11 REFERENCES ............................................................................................................................................. 54 
12 APPENDIX .................................................................................................................................................... 56 
12.1  Participating Centers  ........................................................................................................................ 56 
12.2  Blood collection schedule (amounts in mL)  .................................................................................. [ADDRESS_272292]  Protocol #  [ADDRESS_272293] Protocol -  Version 1.3  Confidential, not for distribution  1  
STATEMENT OF COMPLIANCE  
 
The trial will be conducted in accordance with the International Conference on Harmonisation Guideline for Good 
Clinical Practice (ICH GCP), the [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies, and the terms and conditions of the award fr om the National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK). The Principal Investigators will assure that no deviation from or changes to the protocol take place without 
prior agreement from the Investigational New Drug (IND) sponsor, p rior agreement from the funding agency, and 
documented approval from the Institutional Review Board (IRB) serving as the IRB for the trial, except where necessary 
to eliminate an immediate hazard(s) to the trial participants.  All personnel involved in the conduct of this study have 
completed Human Subjects Protection and ICH GCP  Training.  
 The protocol, informed consent form(s), recruitment materials, and participant materials will be submitted to the IRB for review and approval prior to use. Any amendment to the protocol will first require review and  approval by [CONTACT_226544], then by [CONTACT_1201] b efore the changes are implemented. All changes to the consent form will be approved prior to 
implementation; a determination will be made regarding whether a new consent needs to be obtained from participants who provided consent using a previously approved consent form. Any protocol amendments will be sent to the FDA.  
 
1  PROTOCOL SUMMARY  
1.1 SYNOPSIS  
Title:  Buspi[INVESTIGATOR_226434]: A 
Multicenter, Randomized, Placebo -Controlled, Double -masked Trial 
(BESST).  
Study Description:   
This is a multi -center, randomized, double-masked, placebo -controlled, 
parallel treatment groups phase [ADDRESS_272294] 
moderately severe symptoms of early satiety and/or postprandial fullness. 
After enrollment, participants age d 18-85  years will be treated with 
buspi[INVESTIGATOR_5331] (10 mg three times per day) or a matching placebo for [ADDRESS_272295] -treatment washout period. The primary 
outcome for the study is  the 4-week change (week 4 minus baseline) in the 
4-item  postprandial fullness/early satiety subscore (higher score s indicate 
worse symptoms)  from the Patient Assessment of Gastrointestinal 
Disorders Symptom Severity Index  (PAGI -SYM ) questionnaire.  We 
hypothesize that 10 mg t.i.d. buspi[INVESTIGATOR_226435] e mean 
postprandial fullness/early satiety symptom  severity subscores over 4 -
weeks compared to treatment with placebo . 
 
Objectives:  
 Primary Objective: To determine whether [ADDRESS_272296], compared to treatment with  
placebo improves symptoms of postprandial fullness and early satiety as indicated by [CONTACT_226545]-SYM questionnaire’s postprandial 
fullness/early satiety subscore  (score at 4 -weeks minus score at baseline ). 
BESST  Protocol #  [ADDRESS_272297] Protocol -  Version 1.3  Confidential, not for distribution  2  
Secondary Objectives :  To determine whether 4 weeks of treatment with 
buspi[INVESTIGATOR_226436], and other participant  clinical 
characteristics ( gastric retention , anxiety, depression, quality of life ) and to 
determine the safety and tolerability of buspi[INVESTIGATOR_226437] . 
 
Outcome s: Primary Outcome:  The primary outcome is the change in the postprandial 
fullness/early satiety subscore from baseline to 4 weeks; this subscore is 
calculated by [CONTACT_226546] 4 PAGI -SYM  questionnaire items: 
stomach fullness, inability to finish a normal -sized meal, feeling excessively 
full after meals, and loss of appetite.  
 
Secondary Outcomes : Changes over  4-weeks (week 4 minus baseline) in:  
1. Gastroparesis Cardinal Symptom Index  (GCSI ) total score ; 
GCSI is comprised of  the first 9 -items of the PAGI -SYM 
questionnaire. 
2. Four PAGI -SYM questionnaire subscores: nausea/vomiting  (3 
items: nausea, retching, vomiting), bloating (2 items: bloating, 
stomach visibly larger), upper abdominal pain  (2 items: upper 
abdominal pain, upper  abdominal discomfort), GERD  (7 items: 
heartburn during the day, heartburn when lying down, feeling of 
discomfort inside chest during the day, feeling of discomfort 
inside chest during sleep, regurgitation or reflux during the day, 
regurgitation when lying  down, bitter, acid or sour taste in  
mouth)  
3. Eight single -item PAGI -SYM  questionnaire symptom severity 
scores: nausea, vomiting, stomach fullness, inability to finish a 
normal -sized meal, feeling excessively full after meals, loss of 
appetite, bloating, upper abdominal  pain  
4. Gastrointestinal Symptom Rating Scale (GSRS) total score  
5. Clinical Patient Grading Assessment Scale (CPGAS)  score  
6. Patient Assessment of Upper Gastrointestinal Disorders-Quality of 
Life ( PAGI -QOL ) questionnaire total score  
7. Hospi[INVESTIGATOR_5620]  (HADS) questionnaire 
anxiety score and depression score 
8. Patient Health Questionnaire  15 Somatic Symptom Severity Scale  
(PHQ -15) questionnaire total  somatization score  
9. SF-36v2 Quality of Life questionnaire Physical Component Score 
and Mental Component Score 
10.  Percent gastric emptying retention  at 2 and 4 -hours . 
11. Anthropometric measurements (Body Mass Index (BMI)/ 
weight, waist  circumference) (safety)  
12.  ECG measures (safety)  
13.  Laboratory measure s (ALT, creatinine, glucose) (safety)  
14. Frequency of side effects and adverse events, as well as severity 
of adverse events. (safety  and tolerability ) 
 
BESST  Protocol #  [ADDRESS_272298] Protocol -  Version 1.3  Confidential, not for distribution  3  
Exploratory/Ancillary Outcomes:  These outcomes either use novel 
techniques  (items 1, 2 , and 3) or are out comes that have lower statistical 
power yet might provide insight into paths for future research (items 4,5) . 
The outcome measures are c hanges over 4 weeks  (week 4 minus baseline) 
in: 
1. Intragastric meal distribution  (IMD) as a measure of 
Fundic Accommodation (FA) using digital analyses of 
the GES test  images  
2. Gastric dysrhythmia and volume of water consumed 
until full measured with  electrogastrogram  (EGG ) 
with water load satiety test 
3. GCSI -DD total score and single -item scores on the ANMS 
GCSI -DD questionnaire: nausea, postprandial fullness, 
early satiety, upper abdominal pain, epi[INVESTIGATOR_114128], 
epi[INVESTIGATOR_226438], overall symptom severity; this 
instrument is completed daily and the score for an item at 
a time point is the average score for the item over the 
past [ADDRESS_272299] 7 days minus the average for the 7 - 
days of baseline completion  
4. 12 symptom severity items measured on the PAGI -SYM 
questionnaire and not included in secondary outcomes 
item 3, including retching, lower abdominal pain, lower 
abdominal discomfort, constipation, and  diarrhea  
5. 5 subscores of the Gastrointestinal Symptom Rating Scale  
(GSRS)  questionnaire 
 
Study Population:  The study population will be [ADDRESS_272300] moderately severe 
postprandial fullness and/or early satiety and other symptoms of gastroparesis.  
 
Phase:  Phase 2  
Description of 
Sites /Facilities Enrolling 
Participants : Participants will be recruited from the six clinical sites of the GpCRC 
located throughout the [LOCATION_002].  (see 12.1 for sites)  
 
Description of Study  
Intervention:  • Group 1: Buspi[INVESTIGATOR_5331] 10 mg capsule three times daily, 30 minutes 
before each meal, for 4  weeks  
• Group 2: Matching oral placebo capsule three times daily, 30 minutes 
before each meal, for 4  weeks  
 
Total Study Duration:  137 weeks ( 31.5  months)  
• Recruitment: 131 weeks ( 30 months ) 
• Participant  follow -up: 6 weeks  
• Expected enrollment rate: ~1 (.6 ) participant per month per 
clinical center (18 participants each at 6 center s) 
 
BESST  Protocol #  [ADDRESS_272301] Protocol -  Version 1.3  Confidential, not for distribution  4 Participa nt Duration:  Up to 14 weeks  
• Up to 8 weeks of screening prior to  randomization  
• 4 weeks of treatment starting at randomization  
• 2 weeks' post -treatment period 
 
Inclusion Criteria:    
• Age 18 to 85 years of age at the initial screening  interview  
• Symptoms compatible with gastroparesis or other functional 
gastric disorder for at least 3 months (does not have to be 
contiguous) prior to the initial screening interview  
• Diagnosis of either diabetic or  idiopathic  gastroparesis 
• Delayed or normal gastric emptying retention on screening [ADDRESS_272302] 
• Symptoms of gastroparesis measured by [CONTACT_941] 9 -item PAGI -SYM 
Gastroparesis Cardinal Symptom Index (GCSI) total score > 2.0 at  
enrollment  
• Symptomatic with postprandial fullness/early satiety severity at enrollment  using the PAGI -SYM questionnaire postpra ndial  
fullness/early satiety subscore ≥  3 
• Upper endoscopy or upper GI series without ulcers or mass  
lesions  in the 2 years prior to enrollment  
Exclusion Criteria:  
  
• Post -surgical gastroparesis, including prior pyloromyotomy, pyloric 
resection, vagotomy, bariatric surgery , or post -Nissen fundoplication  
• Another active disorder that could explain symptoms in the 
opi[INVESTIGATOR_871]  
• Concurrent u se of opi[INVESTIGATOR_226439] 3 days  per 
week  
• Significant hepatic injury as defined by [CONTACT_14427] (ALT) 
elevation of greater than 2xULN or a Child -Pugh score of 10 or greater  
• History of significant cardiac disorders (prior heart attack, prior stroke, unstable angina) or significant cardiac arrhythmias or ECG abnormal ities defined as history of, or current, arrhythmias 
including ventricular tachycardia, ventricular fibrillation and Torsade des Pointes and/or prolonged QTc on ECG (>450 msec 
for men and >470 for women)  
• History of chronic kidney disease or on hemodialysis  or 
peritoneal dialysis  
• Impaired renal function as defined by [CONTACT_226547] (eGFR) < 60 ml/min/1.73
2 using the Chronic Kidney Disease 
Epi[INVESTIGATOR_10444] (CKD -EPI) calculator  
• Uncontrolled  diabetes defined as HbA1c (%) of 10% or more within 60 
days of enrollment  
• Allergy to buspi[INVESTIGATOR_5331]  
• Concurrent or prior use (within 30 days) of monoamine oxidase ( MAO ) 
inhibitors  
• Concurrent or prior use (within 30 days) of benzodiaz epi[INVESTIGATOR_226440] #  [ADDRESS_272303] Protocol -  Version 1.3  Confidential, not for distribution  5   • Concurrent or prior use (within 30 days) of b uspi[INVESTIGATOR_5331], warfarin, 
haloperidol, and drugs to treat seizures (e.g., phenytoin and 
carbamazepi[INVESTIGATOR_050])  
• For women of child -bearing potential, either pregnancy, planned 
pregnancy, unwillingness to use effective birth control during the trial or, breast feeding  
• Any other condition, which in the opi[INVESTIGATOR_226441]  
• Failure to give informed  consent  
BESST  Protocol #  [ADDRESS_272304] Protocol -  Version 1.3  Confidential, not for distribution  6 1.2 SCHEMA  
 
Screening:  
Prior to  
Enrollment  
 
 
 
       ↓ 
  
Visit 1   
Day 0  
    ↓       ↓ 
            
 
 
 
   
    ↓       ↓ 
        
↓ 
 
Visit 2  
Week 2  
        
↓ 
 
Visit 3  
Week 4  
 
        
↓ 
 
Visit 4  
Week 6  
 
        
 
 
 
  Screening and Baseline: Obtain informed consent. Screen potential 
participants  for eligibility using inclusion /exclusion criteria . Obtain baseline 
assessments: physical exam, anthropometrics, medical histor y, gastroparesis 
questionnaires, GES, EGG with water load test. Draw blood for plasma, serum , 
metabolic panel , TSH, and banking. Pregnancy test for females.  
(See 1.3 Schedule of Activities)  
 
Follow -up (primary outcomes): Repeat baseline assessments. Record adverse 
events, symptoms, and medication side effects since last visit. Repeat pregnancy 
test.   
(See 1.3 Schedule of Activities ) 
 Arm 2 = 
PLACEBO 
(N=54)  Arm 1 =  
BUSPI[INVESTIGATOR_226442] 
(N=54)  
Follow -up assessments of study objectives and adverse effects, p hysical exam,  
symptom side effects, pregnancy test , questionnaires. 
(See 1.3 Schedule of Activities ) 
Follow -up (washout/post treatment):  Repeat baseline assessments. Record 
adverse events and symptoms since last visit.  
(See 1.3 Schedule of Activities )  
Randomize and Dispense buspi[INVESTIGATOR_5331] (Arm 1) or placebo (Arm 2)  
BESST  Protocol #  [ADDRESS_272305] Protocol -  Version 1.3  Confidential, not for distribution  7 1.3 SCHEDULE OF ACTIVITIES ( SOA ) 
 Screening 
visits   Follow -up visits - 
Weeks from Randomization  
Assessment/Procedure   RZ F02 F04* F06 
Consent, HIPAA authorization, demographics  X . . . . 
Baseline medical history  X . . . . 
Follow -up medical history  . . X X X 
Side effects survey  X . X X X 
Review for adverse effects  . . X X X 
Review for concomitant medications  X X X X X 
Hospi[INVESTIGATOR_226443] (HADS)  X . X X X 
SF-36v2 Quality of life  X . . X     . 
PAGI -SYM questionnaire  (includes the GCSI)  X . X X X 
Gastrointestinal Symptom Rating Scale (GSRS)  X . . X X 
PAGI -QOL questionnaire  X . . X X 
Patient Health Questionnaire (PHQ -15) X . . X     . 
Clinical Patient Grading Assessment Scale (CPGAS)   . X X X 
Detailed (D) or focused (F) physical exam  D F F D D 
Gastric emptying Scintigraphy  (GES) test  X . . X . 
Electrogastrogra m (EGG) with water load test * X . . X . 
Provide supplies of GCSI -DD X X X X . 
Collection  of participant’s  completed GCSI -DD . X X X X 
Standard of care materials provided  . X . . . 
Eligibility confirmation  X X . . . 
Study drug dispensing  . X . . . 
Review of study drug adherence  . . X X . 
Labs:  
Complete blood count (CBC)   
X  
.  
.  
X  
X 
Comprehensive metabolic panel (CMP)  X . . X X 
Thyroid stimulating hormone (TSH)  X . . . . 
Fasting HbA1c  X . . . . 
Pregnancy test  X X X X . 
      
Banking: Fasting serum and plasma  X . . X X 
Complete Case Report Forms (CRFs)  X X X X X 
Closeout form      X 
Detailed physical exam  (D): anthropometric assessments (body weight [kg], body height [m], waist circumference [cm], 
and hip circumference [cm]); vital signs (temperature, heart rate, respi[INVESTIGATOR_697], blood pressure), organ systems chest, 
lungs, heart, abdomen, liver and spleen, ner vous), resting electrocardiogram (ECG)  
Focused physical exam  (F): anthropometric assessments (body weight [kg], body height [m], waist circumference 
[cm], and hip circumference [cm]); vital signs (temperature, heart rate, respi[INVESTIGATOR_697], blood pressure)  
Complete blood count (CBC): concentration of white blood cells (WBC), red blood cells, hemoglobin, hematocrit, 
platelet count  
Comprehensive metabolic panel (CMP): glucose, calcium, sodium, potassium, CO2 (carbon dioxide/bicarbonate), chloride,  
blood  urea  nitrogen  (BUN),  creatinine,  total  protein,  albumin,  total  biliru bin, alkaline  phosphatase  (ALP), aspartate 
aminotransferase (AST), alanine aminotransferase  (ALT) 
Thyroid Stimulating Hormone test (TSH)  
*The EGG with water load test is scheduled for a separate day than the GES testing at Screening and F04 week visits.  
  
BESST  Protocol #  [ADDRESS_272306] Protocol -  Version 1.3  Confidential, not for distribution  8  
2  INTRODUCTION  
 
2.1 STUDY R ATIONALE   
 
Gastroparesis is a chronic symptomatic disorder associated with delayed gastric emptying  [1].  Gastroparesis 
predominantly affects young women (females outnumber males by a ratio of 4:1, the average age is 34). The 
symptomatic profile of gastroparesis includes nausea (90% of patients), vomiting (>80%), bloating (75%), early 
satiety (60%), and abd ominal pain (approximately 50%)  [2]. Symptoms in individual patients can vary in both their 
combination and their severity. Because of its chronic and often intractable nature, the disorder has a tremendous 
impact on both patients and  society.  
 
Gastroparesis remains difficult to treat, in large part because of the lack of knowledge of the underlying pathophysiology. Several factors in particular have impeded progress in this field, including the paucity of patients 
seen by [CONTACT_226548], the absence of uni form diagnostic criteria, and the lack of generally available and reliable 
methods for physiological testing. Given the complexity of the disorder and its profound degree of morbidity, an 
important need exists to appropriately study new treatments for pati ents . 
 
A variety of agents have been used for the treatment of gastroparesis  [1,3]. These include classic agents such as 
prokinetic metoclopramide, cisapride (restricted use) and domperidone (not available in the U.S.). The track 
record of these drugs is mixed at best, a problem compounded by [CONTACT_226549]. A meta -
analysis has suggested that in double-blind, controlled studies, cisapride produced a mean improvement in 
symptom score of only 8%, whereas metoclopramide produced a mean imp rovement of 36%. Also, improvement 
in symptoms generally does not correlate well with changes in gastric emptying. This is important as it reinforces 
the concept that symptoms are not necessarily being driven by [CONTACT_226550]. There is, therefore, a 
need for new and innovative approaches to evaluation and treatment of symptoms of gastroparesis . 
 
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) established the Gastroparesis 
Clinical Research Consortium (GpCRC) in [ADDRESS_272307] multicenter observational studies and randomized, controlled treatment trials on well -characterized 
patients with gastroparesis. The GpCRC is a cooperative network of six clinical sites and one Scientific Data 
Research Center (SDRC). The individual clinical centers participate in a cooperative and interactive manner with 
one another and wit h the SDRC in all aspects of the GpCRC . 
 
In a substantial number of patients who present with symptoms suggestive of gastroparesis (e.g., chronic nausea, vomiting, early satiety, postprandial fullness), gastric emptying tests are normal. Although the patho genesis of 
symptoms in these patients is not known, it is presumed that most have some form of gastric dysfunction. Further, they appear to have a demographic and clinical profile that is nearly indistinguishable from classical gastroparesis and their trea tment remains just as challenging.  The GpCRC uses  the term Chronic Unexplained Nausea and 
Vomiting (CUNV) to describe this group of patients. Both groups of patients will be eligible for the GpCRC BESST . 
  
BESST  Protocol #  [ADDRESS_272308] Protocol -  Version 1.3  Confidential, not for distribution  9  
2.2 BACKGROUND   
 
Normally with food ingestion, the proximal 
stomach relaxes, with an increase in volume, 
allowing the proximal stomach to accommodate 
the ingested meal [ 4,5]. This is followed by 
[CONTACT_226551].  Withi n the antrum, regular 
peristaltic contractions grind down solid food to 
smaller particles that can be passed through the 
pyloric sphincter into the small intestine for 
absorption. This is illustrated in the figure on the 
right  [6]. 
 
 
Patients with gastroparesis have symptoms of early satiety, postprandial fullness, nausea, vomiting,  and/ or 
abdominal pain. It is now better appreciated that symptoms of gastroparesis are not well correlated with current 
standardized gastric emptying results which asses s only total gastric emptying [7]. As noted above, some patients 
have symptoms similar to gastroparesis but normal gastric emptying, an entity that the GpCRC has called CUNV (defined above) [8]. For this reason, the successful GpCRC APRON trial of aprepi[INVESTIGATOR_140609]. placebo enrolled patients 
with nausea and vomiting, whether with delayed or normal emptying [9]. 
 
Impaired gastric accommodation to a meal may also cause postprandial symptoms [10] . With impaired 
accommodation , there is increased pressure in the upper stomach which compromises the ability of the upper 
stomach to act as a reservoir for ingested food, resulting in rapid transit of food into the distal stomach. Impaired 
accommodation has been shown to be associated with early satiety and weight loss in both functional dyspepsia 
[11] and idiopathic gastroparesis [12] . Accommodation can be assessed with barostat, gastric mucosal labeling with 
single photon emission computed tomography (SPECT) imaging, and magnetic resonance imaging. Although much 
has been learned with these technologies, they are costly and time consuming and not used routinely in clinical 
evaluation of patients. Gastric emptying scintigraphy (GES) measures overall gastric retention of the ingested meal over time; it can also assess, in the same study, intragastric meal di stribution  (IMD) [13]. With normal fundic 
accommodation  (FA), the food initially resides in the proximal portion of the stomach, whereas with impaired 
accommodation, the food is quickly transferred to the antrum [12]. Including assessment of intragastric meal 
distribution as part of a standard GES study will permit improvement in the assessment of the relationship between symptoms of gastroparesis with abnormal gastric motility. This additional information may lead to therapy directed 
to improve gastric acc ommodation . 
 
Use of GES to assess proximal gastric accommodation was originally suggested in observational studies by [CONTACT_226552], et al [12]. Using scintigraphy in patients with functional dyspepsia Pi[INVESTIGATOR_223671], Tack et al quantitated the ratio of the 
proximal  gastric counts to the distal gastric counts [14]. Forty -five percent  of patients had distal redistribution of the 
solid phase of the meal. Early satiety was associated with early distal redistribution, suggesting impaired fundic 
accommodation . 
 
In the GpC RC BESST, images from GES will be analyzed for intragastric meal distribution (IMD) as an  assessment 
of transit through the stomach and fundic accommodation. We have previously described proximal retention in 
GERD, distal retention in functional dyspepsia, and global retention in gastroparesis [15] . A recent preliminary 
study performed by [CONTACT_3019] [16] showed that  impaired gastric accommodation  can be evaluated visually using current 
standardized solid -meal GES images. A simple visual assessment of normal gastric accommodation  defined as 

BESST  Protocol #  [ADDRESS_272309] Protocol -  Version 1.3  Confidential, not for distribution  10 visualization of the majority of gastric activity (e.g. >50%) being present in  the upper portion of the stomach in 
the first set of post -meal ingestion (t=0 minutes) images was used. The upper stomach was defined as the portion 
of the stomach that extends from the fundus to the incisura. Overall, impaired gastric accommodation  was 
significantly associated with the severity of early satiety and stomach fullness. Impaired gastric accommodation  
in patients with normal GES was associated with early satiety, whereas impaired gastric accommodation  in 
patients with delayed gastric emptying was associated with stomach fullness and postprandial fullness. Thus, this 
study showed that routine visual assessment of gastric accommodation  as a part of a GES study may allow for 
better correlation of symptoms to abnormalities of gastric  motility . 
 
GpCRC investigators have been assessing regional gastric transit in the GES studies of the patients in the 
Gastroparesis Registry 2. We developed a semi -automated analysis of regional intragastric meal distribution 
during GES. The scintigraphic images were  read using a GPCRC-developed application written for MATLAB 
software, which has a freely available runtime environment. We designed the application to construct the longitudinal axis of the stomach and subdivide the stomach into two (proximal, distal) regions of interest, 
allowing assessment of the meal distribution during the test. The amount in the proximal region of interest 
provides a measure of fundic accommodation  (FA). From our preliminary data, 8 patients with visually impaired 
gastric accommodation had less percent radioactivity in the proximal stomach at time 0 (55.7±9.1%) than the 16 
patients with normal accommodation (83.7±7.7%) and 20 normal subjects (82.6±9.6%). Examples and figure below :  
 
Normal  intragastric  meal  Rapid proximal 
gastric distribution at  time  0. transit  
(normal accommodation)  (impaired  accommodation)  
 
 
We have thus achieved the first really semi-automated computer approach to analyzing GES images.  This unique 
analysis offers additional promise to more fully automat e analysis of GES. Our studies have shown that fundic 
accommodation can be assessed visually during routine GES with moderate pairwise agreement and high panel 
consistency among nuclear medicine physicians  using the  semi-automated software quantified IMD with an 
optimum cutoff of IMD<0.568 to define abnormal IMD/impaired FA  [17].  Abnormal IMD was significantly 
associated with early satiety, loss of weight, and low BMI and was seen predominantly in nondiabetic patients. 
Assessment of fundic accommodation during GES is associated  with several important patient clinical findings 
and symptoms. This approach will be used in this GpCRC BESST trial to help understand the mechanism of action 
of buspi[INVESTIGATOR_5331].  
 
In addition, as a prelu de to BESST, we assessed our patients in Gastroparesis Registry 2 (GpR 2),  for the relationship 
of early satiety  to patient characteristics  [18]. We specifically wanted to assess relationships of early satiety with 
etiology of gastroparesis, quality of life, body weight, gastric emptying, and water load testing. 165 patients with 
gastroparesis (111 IG, 54 DG) were assessed. Early satiety  was severe or very severe in 83 of 165 (50%) patients. 
Severity scores for early satiety were similar between idiopathic and diabetic gastroparesis. Increasing severity of 
early satiety  was associated with increasing gastroparesis severity (p=0.0008), decreasing BMI (p=0.006), decreased 
quality of life from PAGI -QOL (p=0.06) and SF -36v2  physical health  summary score (p=0.05). Increasing severity of 
early satiety  was associated with increasing gastric retention of a solid meal at 4 hours (p=0.03) and decrease in 

BESST  Protocol #  [ADDRESS_272310] (p=0.02). Thus, early satie ty is a common symptom in both diabetic and 
idiopathic gastroparesis. Early satiety  severity is associated with measures of gastroparesis severity, body weight, 
quality of life, gastric emptying, and water load testing. These relationships make early satie ty an important 
symptom characterizing gastroparesis . 
 
In BESST,  we will investigate an agent that improves fundic accommodation and determine its impact on 
improving symptoms, specifically early satiety and postprandial  fullness.  Buspi[INVESTIGATOR_131521] a [ADDRESS_272311] drugs predominantly used to treat anxiety, 
buspi[INVESTIGATOR_5331]'s pharmacology is not related to benzodiazepi[INVESTIGATOR_226444], an d so it does not carry the risk of 
physical dependence and withdrawal symptoms for which those drug classes are known .  
 
The proximal gastric fundus tone is mediated by a balance of excitatory cholinergic and inhibitory non -
adrenergic, none-cholinergic  (NANC ) neural input. Recently, [ADDRESS_272312] includi ng the stomach [19] . Buspi[INVESTIGATOR_226445] [ADDRESS_272313] in both in vitro and in vivo experimental models using guinea pi[INVESTIGATOR_14107]. 
Buspi[INVESTIGATOR_5331]’s effect on improving gastric accommodation  has also been shown in stu dies in normal subjects [20] . 
In these normal subjects, buspi[INVESTIGATOR_226446] [ADDRESS_272314]. In studies of patients with functional dyspepsia, buspi[INVESTIGATOR_5331] 10 mg three times daily in a 4 -week study improved gastric accommodation  and 
symptoms of early satiety, postprandial fullness, and bloating [21] . In this study of pat ients with functional 
dyspepsia, buspi[INVESTIGATOR_226447],  but 
slightly delayed gastric emptying of liquids. Interestingly, acute anxiety and anxiety disorders have been reported to  impair gastric accommodation  (22). 
  
 
2.3 RISK/BENEFIT ASSESSMENT    
2.3.1  KNOWN POTENTIAL RISKS  
 
Risks of buspi[INVESTIGATOR_5331]: Common buspi[INVESTIGATOR_226448]: headache; dizziness, tiredness, drowsiness, and 
lightheaded feeling; sleep problems (insomnia); nausea, upset stomach ; blurred vision; nervousness or 
excitement, nonspecific chest pain; sore throat, nasal congestion, tinnitus; and rarely, tardive dyskinesia. Common drug interactions of buspi[INVESTIGATOR_226449] (MAO) inhibitors. Thus far, there is no direct 
evidence that buspi[INVESTIGATOR_226450]-seeking behavior.  
 
Interference with cognitive and motor performance :  Studies indicate that buspi[INVESTIGATOR_226451]. However, its 
central nervous system effects in any individual participant may not be predictable. Therefore, participants 
should be cautioned about operati ng an automobile or using complex machinery until they are reasonably 
certain that buspi[INVESTIGATOR_226452]. In general, because the effects of concomitant 
administration of buspi[INVESTIGATOR_226453] (CNS -active) drugs have  either not been studied or validated, 
the concomitant use of psychotropic drugs and buspi[INVESTIGATOR_226454] . 
 
While formal studies of the interaction of buspi[INVESTIGATOR_226455]-induced impairment in motor and mental performance, it is prudent to avoid concomitant use 
of alcohol and buspi[INVESTIGATOR_5331].  
 
  
BESST  Protocol #  [ADDRESS_272315] Protocol -  Version 1.3  Confidential, not for distribution  12 Potential for Withdrawal Reactions in Sedative/Hypnotic/ anxiolytic drug-dependent participants :  
Because buspi[INVESTIGATOR_226456] -tolerance with benzodiazepi[INVESTIGATOR_226457]/hypnotic drugs, it will not block the withdrawal syndrome often seen with cessation of therapy with 
these drugs. Therefore, before startin g therapy with buspi[INVESTIGATOR_226458], it is advisable to withdraw 
participants gradually from their prior treatment, especially participants who have been using a CNS depressant drug chronically. Rebound or withdrawal symptoms may occur over  vary ing time  periods,  depending  on the type  
of drug and its effective  half-life of elimination.  
 
The syndrome of withdrawal from sedative/hypnotic/anxiolytic drugs can appear as any combination of irritability, 
anxiety, agitation, insomnia, tremor, abdominal cramps, muscle cramps, vomiting, sweating, flu -like symptoms 
without fever, and occasionally, even seizures.  
 
General risks : The condition of the participant may or may not get better or may become worse while in this 
study. During the study, par ticipants will continue to receive clinical care by [CONTACT_110319].  
 
Stoppi[INVESTIGATOR_226459] : Participants  may remain on their current treatments for gastroparesis , 
including use of a Gastric Electric Stimulator,  if the participant  is on a stable drug dose for at least 3 -months prior 
to enrollment, and is willing to remain on this stable dose throughout the study (including screening, treatment, and post -treatment washout).  The participant  will not need to stop these drugs for the testing days for eith er the 
GES or the EGG with water load procedures.  An exception is that the participant may not take narcotics the [ADDRESS_272316]. If participants are obtaining symptom relief due to any of the exclusionary medications (MAOIs, benzodiazepi[INVESTIGATOR_1651], narcotics more than 3 times per week, warfarin, haloperidol, or drugs to treat seizures ), 
other choices can be arranged with their Primary Care Provider ( PCP)  or the potential participant  will not be able 
to participate in the trial. This possible medicati on regime n change may be inconvenient to the participant but is 
judged to not cause any undue hardship on the participant who  wants to participate in the trial . 
 
Questionnaires : The questionnaires cover demographics, medical history (comorbidities and medications), 
symptoms of gastroparesis, quality of life, and feelings of anxiety and depression. They will take about [ADDRESS_272317] with significant  scores on the Ho spi[INVESTIGATOR_174262] (HADS) questionnaire 
will be referred to a clinical psychologist for follow -up (see section 8.2). 
 
Blood drawing : Blood draw may cause mild discomfort, such as swelling, temporary sen sation of pain, burning, or 
a bruise that may develop and last for a few days. Less common risks include a blood clot at the site of puncture, swelling of the vein and surrounding tissues, and possible bleeding from the puncture site. Very rarely, fainting, 
blood clots or an infection at the site can occur. During the entire study period (up to 14 weeks), subjects will have 
approximately 6 tablespoons of blood drawn ( 88 mL) (see section 12.2) . 
 Electrogastrogram  (EGG) with water load satiety test : EGG testing involves placement of EGG electrodes on the 
abdominal skin. An EGG will be performed twice: during screening and at [ADDRESS_272318] s, which may cause 
inconvenience to the participant.  
 
Gastric emptying scintigraphy  (GES) test : A GES test will be performed twice: during screening and at 4 weeks. 
The total radiation dose for the administration of 0.5 -1 microcuries ( mCi) 99m -Tc sulfur colloid for one GES test is 
an Effective Dose Equivalent of 37-53  millirem  (adult male and adult female, respectively) . The internal organ or 
tissue receiving the highest radiation dose is the upper large intestine, which will receive [ADDRESS_272319]  Protocol #  [ADDRESS_272320] is obtained at study 
screening and at each visit during study treatment to ensure female participants  of child -bearing potential  are not 
pregnant  when exposed to radiation or while taking study drug.  
 
Treatment of side effects:  During BESST, if a participant develops non-life threatening side effects that may be 
attributed to the study drug, the study drug will be stopped only if the participant so desires. If the participant 
chooses to no longer receive the study drug, the part icipant will continue to be followed in the trial, in keepi[INVESTIGATOR_226460] -to-treat paradigm. In the event of major dermatological reactions such as generalized 
urticaria, bullous rashes, exfoliative dermatitis, or Stevens -Johnson Syndrome, study dru g will be discontinued 
immediately. Such s kin reactions are expected to be  infrequent adverse events . 
 
Study visits : This study requires approximately 8  visits to the study center ( up to [ADDRESS_272321] randomization visits) which may cause some inconvenience to some individuals . 
 
Pregnancy : Since there may be unknown risks to pregnant women and their unborn children, potential participants  
who are breast feeding, pregnant, or planning to become pregnant will not be allowed to participate in BESST. Participants  need to confirm to the best of their knowledge that they are not pregnant and if they become pregnant 
during the course of the study, they  must notify the study investigator immediately  and the study drug will  be 
stopped . A urine pregnancy test is obtained at study enrollment and at each visit during study treatment for any 
females of child-bearing potential to help assure that the participant is not pregnan t. 
 
Safety issues related to participant privacy : For this study, data is being recorded about each participant’s medical 
condition via medical records and case report  forms. All data will be kept confidential. Case report  forms on which a 
participant’s data or results from specified procedures have been recorded will be  stored in locked drawers of file 
cabinets.  Study data are  keyed to the GpCRC BESST web-based study data base with encrypted (https:) transmission 
of data and via a secure network using an encrypted, password -protected computer accessible  only by [CONTACT_20234], the site Principal Investigator (PI) , and study -certified study personnel. It is the investigator’s 
responsibility to conduct the protocol under the current version of Declaration of Helsinki, Good Clinical Practice, and the rules of local IRBs. Each investigator must ensure that the participant’s anon ymity is maintained in their data 
submissions to the SDRC . Participants will be identified by  [CONTACT_226553], social security number , address, or hospi[INVESTIGATOR_15168] . Under no circumstances will any 
identifiable data be transmitted and stored in the BESST study data base or be sent in email, scans, or paper -based 
transmissions to the SDRC.  Investigators will locally maintain a separate confidential enrollment log , which links  
identification  codes with  the participants’ names and addresses (i.e., available only to local clinic staff). All study 
material will be maintained in strict confidence . 
  
2.3.2  KNOWN POTENTIAL BENEFITS  
 
Participants may experience short -term relief of the symptoms of anxiety, with low potential of buspi[INVESTIGATOR_226461] -forming.   
 
2.3.3  ASSESSMENT OF POTENTIAL RISKS AND BENEFITS  
 
Justification of the risks: All participants will receive standard of care as part of the trial and will potentially 
benefit if they are in the buspi [INVESTIGATOR_226462].  All of 
BESST  Protocol #  [ADDRESS_272322], improves 
symptoms of early satiety and 
postprandial fullness in 
participants with symptoms of gastroparesis  compared to 
placebo . 
  The primary outcome is the change in 
the PAGI -SYM postprandial 
fullness/early satiety subscore from 
baseline to 4 weeks; this subscore is 
calculated by [CONTACT_226546] 4 
PAGI -SYM  questionnaire  items: 
stomach fullness, inability to finish a 
normal-sized meal, feeling excessively 
full after meals, and loss of appetite.  Buspi[INVESTIGATOR_226463] [ADDRESS_272323] in both in vitro and in vivo 
experimental models using guinea 
pi[INVESTIGATOR_14107], as well as improving gastric accommodation in normal subjects 
and symptoms of early satiety and 
postprandial fullne ss in participants 
with functional dyspepsia. 
(66,67,69).  
Secondary    
The secondary objectives have 
been selected to provide further 
information on whether 4 -weeks of 
treatment with buspi[INVESTIGATOR_226464], and other 
participant  clinical characteristics 
(gastric retention,  anxiety, 
depression, quality of life) and to 
determine the safety and tolerability of buspi[INVESTIGATOR_226465].  
 Change s at 4 weeks  from baseline in 
the following measures:  
(calculated as score at 4 -weeks 
minus score at baseline in:   
1. GCSI total score  
2. Four other PAGI -SYM 
questionnaire  subscores: 
nausea/vomiting (3 items: 
nausea, retching, vomiting), 
bloating (2 items: bloating, 
stomach visibly larger), upper 
abdominal pain (2 items: upper 
abdominal pain, upper abdominal discomfort), GERD  (7 
items: heartburn during the day, 
heartburn when lying down, 
feeling of discomfort inside chest 
during the day, feeling of 
discomfort inside chest during 
sleep, regurgitation or reflux 
during the day, regurgitation when lying down, bitter, acid or 
sour taste in  mouth)  
3. Eight single -item PAGI -SYM 
symptom severity scores: Nausea, 
vomiting, stomach fullness, inability 
to finish a normal -sized meal, These outcomes were selected 
because they measure important gastroparesis symptoms or co- 
morbidities of gastroparesis and are 
useful for determining if buspi[INVESTIGATOR_226466] . 
BESST  Protocol #  [ADDRESS_272324] Protocol -  Version 1.3  Confidential, not for distribution  15 OBJECTIVES  OUTCOMES  JUSTIFICATION FOR 
OUTCOMES  
feeling excessively full after meals, 
loss of appetite, bloating, upper 
abdominal pain 
4. Gastrointestinal Symptom Rating 
Scale (GSRS) total score  
5. Clinical Patient Grading Assessment 
Scale (CPGAS)  score  
6. Patient Assessment of Upper 
Gastrointestinal Disorders -Quality 
of Life (PAGI -QOL) total score  
7. Hospi[INVESTIGATOR_226467]  (HADS) anxiety score and 
depression score  
8. Patient Health Questionnaire 15 Somatic Symptom Sev erity Scale 
(PHQ-15) total  somatization score  
9. SF-36v2 Quality of Life 
questionnaire, Physical Component Score and Mental Component Score  
10.  Percent gastric emptying retention 
at 2 and 4 -hours  
11. Anthropometric 
measurements (Body Mass 
Index (BMI)/weight, waist  
circumference) (safety)  
12.  ECG measures (safety)  
13.  Laboratory measures (ALT, 
creatinine, glucose) (safety)  
14. Frequency of side effects and 
adverse events, as well as severity 
of adverse events. (safety and 
tolerability)  
 
Tertiary/Exploratory  Change s from screening to 4 weeks:   
Tertiary: exploratory/ancillary  
objectives were selected as a basis 
for explaining or supporting findings of the primary analysis and 
key secondary outcomes in 
sensitivity analyses and for suggesting further hypotheses for 
future research.  
 Change s at 4-weeks from baseline 
(calculated as score at 4 weeks minus 
score at baseline) in:  
1. Intragastric meal distribution as an 
assessment of Fundic 
Accommodation (FA) using digital 
analyses of the GES test images  
2. Gastric rhythm and water ingestion 
when full measured with EGG with water load test.  
3.  ANMS GCSI -DD 7 item  scores : 
nausea, postprandial fullness, early satiety, upper abdominal pain,  
Fundic accommodation (FA) is the primary target of the [ADDRESS_272325] and will provide 
information on the hypothesis of 
action of buspi[INVESTIGATOR_226468] 
(item 1).  
 
Gastric dysrhythmia outcomes from 
the EGG water load test will help to 
provide insight into the action of 
buspi[INVESTIGATOR_226468] (item 2).  
 
BESST  Protocol #  [ADDRESS_272326] Protocol -  Version 1.3  Confidential, not for distribution  16 OBJECTIVES  OUTCOMES  JUSTIFICATION FOR 
OUTCOMES  
epi[INVESTIGATOR_114128], epi[INVESTIGATOR_226469], overall symptom severity; 
each single item score is the 
average of the daily score from the 
last 7 days  
4.  Each of the 15 symptom severity 
items measured on the PAGI -SYM 
questionnaire  not included in 
secondary o utcomes item 3, 
including retching, lower abdominal pain, lower abdominal discomfort, 
constipation, and  diarrhea  
5.  Each of the 5 subscores of the 
Gastrointestinal Symptom Rating 
Scale (GSRS).  The ANMS GCSI -DD uses a Patient -
Reported Outcome ( PRO ) daily -diary 
to capture symptoms of 
gastroparesis; however, this instrument is still being validated 
(item 3).  
 
Improvements in other  
gastroparesis symptoms will be explored to study possible other 
effects of buspi[INVESTIGATOR_5331] (items 4, 5).  
 
 
 
4 STUDY DESIGN  
4.1 OVERA LL DESIGN  
• The primary hypothesis of the trial is that buspi[INVESTIGATOR_226470] -SYM questionnaire postprandial fullness/early satiety subscore; we 
will test this hypothesis by [CONTACT_226554] 4 weeks 
of treatment in the group treated with buspi[INVESTIGATOR_226471] (ANCOVA test for mean between -group differences in differences using 
baseline value as the covariate ) 
• Phase  2 
• A multi -center, randomized, double -masked, placebo -controlled, parallel treatment groups phase 2 trial 
with primary outcome defined as symptomatic improvement in early satiety  and postprandial fullness .  
The primary ou tcome is the change in the postprandial fullness/early satiety subscore from baseline to 4 
weeks; this subscore is calculated by [CONTACT_226546] 4 PAGI -SYM  questionnaire items: stomach 
fullness, inability to finish a normal -sized meal, feeling excessively full after meals, and loss of appetite.  
• Methods to decrease bias will include placebo control, double masking and  randomization.  
• Two study  arms  
• Multisite  
• Study intervent ion is  buspi[INVESTIGATOR_5331] 10 mg capsule three times daily, 30 minutes before each meal, for 4 
weeks or matching placebo. 
• The randomization design will be stratified by [CONTACT_226555]’ assignments into one of 
two groups (buspi[INVESTIGATOR_226472]) in permuted blocks of random length within each clinic.  
 
4.2 SCIENTIFIC R ATIONALE FOR STUDY DESIGN  
 
The study design is a multi -center, randomized, double-masked, placebo -controlled, parallel treatment groups 
phase 2 trial.  
 
Rational e for a Placebo Group: Currently, there are few effective treatments for symptoms in participants with 
gastroparesis and related syndromes. Studies of various agents have shown placebo effects ranging from 10% and 
BESST  Protocol #  [ADDRESS_272327] Protocol -  Version 1.3  Confidential, not for distribution  17 higher. In the NIDDK GpCRC Aprepi[INVESTIGATOR_226473] t he Relief of Nausea (APRON) trial, 40% of the participants treated with 
placebo improved on the primary outcome [9]. In the NIDDK GpCRC 48 -week Outcomes paper, approximately 28% 
of the participants showed substantial symptomatic improvement at [ADDRESS_272328] of Care (SOC) [23] . 
Therefore, it is important to have a placebo group to be able to discriminate a treatment effect over and above 
SOC and the lifestyle advice provided to all of these participants.  
 
In addition, in order to assess the efficacy of an agent in gastroparesis, a placebo group is needed to determine 
the relative efficacy in improving symptoms and physical functions. In order to have the highest quality of 
evidence to test our hypothesis, the BESST trial uses a randomized, do uble- masked, placebo -controlled study 
design.  
 
The trial is double-masked to prevent bias by [CONTACT_226556]. The trial is 4 weeks since the Minimum Clinically Important Difference (MCID) in gastroparesis symptoms has been shown in the liter ature to 
be detected in that timeframe. The trial is powered at 90% to detect a MCID in the PAGI -SYM questionnaire  
postprandial fullness/early satiety subscore primary outcome measure; it is powered at 80% to detect a MCID in 
the GCSI total score, the key secondary outcome . 
 
4.[ADDRESS_272329] drugs predominantly used to treat anxiety, buspi[INVESTIGATOR_5331]'s pharmacology is not related  to benzodiazepi[INVESTIGATOR_226474], and so does not carry the risk of physical dependence and withdrawal symptoms for which those 
drug classes are know n. The proximal gastric fundus tone is mediated by a balance of excitatory cholinergic and 
inhibitory non-adrenergic, none- cholinergic (NANC)  neural input. Recently, [ADDRESS_272330] incl uding the stomach [19] . 
 
Buspi[INVESTIGATOR_226475] [ADDRESS_272331] in both in vitro and in vivo 
experimental models using guinea pi[INVESTIGATOR_14107].  Buspi[INVESTIGATOR_5331]’s effect on improving gastric accommodation has also been shown in st udies in normal subjects [20]. In these normal subjects, buspi[INVESTIGATOR_226476] [ADDRESS_272332].  
 
In studies of participants with functional dyspepsia, buspi[INVESTIGATOR_5331] 10 mg three times daily in a 4 -week study improved 
gastric accommodation and symptoms of early satiety, postprandial fullness, and bloating [21]. In this study of 
participants with functional dyspepsia, buspi[INVESTIGATOR_226477].  Interestingly, acute anxiety and anxiety disorders 
have been reported to impair gastric a ccomm odation  [19]. Based on this preliminary data, we will use the same 
dose as used in the functional dyspepsia study.  
 
 
4.[ADDRESS_272333] scheduled procedure (or at the close of the final study visit window) shown in the Schedule 
of Activities (SoA),  Section 1.3.  
 
The end of the study globally is defined as completion of the last study visit (or closure of the final study window) 
shown in the S oA for the last randomized participant . 
BESST  Protocol #  [ADDRESS_272334] meet all of the following criteria: 
• Aged 18 to 8 5 years at initial screening intervie w 
• Symptoms compatible with gastroparesis or other functional gastric disorder for at least 3 months (does not 
have to be contiguous) prior to initial screening interview  
• Diagnosis of diabetic or  idiopathic gastroparesis  
• Delayed or normal gastric  retention on screening [ADDRESS_272335]  
• Symptoms of gastroparesis measured by [CONTACT_941] 9 -item Gastroparesis Cardinal Symptom Index (GCSI) total score 
> 2.0 at  enrollment  
• Symptomatic with postprandial fullness/early satiety severity (PAGI -SYM questionnaire subscale > 3) at 
enrollment  
• Upper endoscopy o r upper GI series without findings of ulcers or mass  lesions in the 2 years prior to enrollment  
 
5.2 EXCLUSION CRITERIA  
 
An individual who meets any of the following criteria will be excluded from participation in this study:   
 
• Post -surgical gastroparesis, including prior pyloromyotomy, pyloric resection, vagotomy, bariatric surgery or post -
Nissen fundoplication  
• Another active disorder which could explain symptoms in the opi[INVESTIGATOR_871]  
• Concurrent use of opi[INVESTIGATOR_226439] 3 days per week  
• Significant hepatic injury as defined by [CONTACT_14427] (ALT) elevation of greater than 2xULN or a Child-
Pugh score of 10 or greater  
• History of significant cardiac disorders (prior heart attack, prior stroke, unstable angina) or significant cardiac arrhythmias or ECG abnormalities defined as history of, or current, arrhythmias including ventricular tachycardia, 
ventricular fibrillation and Torsade des Pointes and/or prolonged QTc on ECG (>450 msec for men and >470 for 
women)  
• History of chronic kidney disease or on hemodialysis or peritoneal dialysis  
• Impaired renal function as defined by [CONTACT_10495] (eGFR) < 60 ml/min/1.73
2 using the 
Chronic Kidney Disease Epi[INVESTIGATOR_10444] (CKD -EPI) calculator  
• Uncontrolled diabetes defined as HbA1c (%) of 10% or more within 60 days of enrollment  
• Allergy to buspi[INVESTIGATOR_5331]  
• Concurrent or prior use (within 30 days) of m onoamine oxidase (MAO) inhibitors  
• Concurrent or prior use (within 30 days) of benzodiazopi[INVESTIGATOR_1651]  
• Concurrent or prior use (within 30 days) of buspi[INVESTIGATOR_5331], warfarin, haloperidol, and drugs to treat seizures (e.g., 
phenytoin and carbamazepi[INVESTIGATOR_050])  
• For women of child -bearing potential, either pregnancy, planned pregnancy, unwillingness to use effective birth 
control dur ing the trial or breast feeding   
• Any other condition, which in the opi[INVESTIGATOR_226478]  
• Failure to give informed consent  
 
5.[ADDRESS_272336]  Protocol #  [ADDRESS_272337] of care (SOC) r ecommendations prepared by [CONTACT_226557]:  
• Standardized set of recommendations on followi ng a Gastroparesis diet.  
• Recommendations on the use of pain medications and to eliminate drugs that might exacerbate the 
underlying dysmotility disorder or prevent the beneficial actions of a prokinetic.  
These recommendations will be included in the BESST Standard of Care Standard Operating Procedures (SOP)  and will 
be provided to each participant . 
 
Also, d uring the BESST  study, participants are asked to:  
• Refrain from consumption of alcohol, grapefruit or grapefruit juice, pomelos, exotic citrus fruits, grapefruit 
hybrids, and fruit juices until after the final dose.  
 
These guidelines are given in the investigator’s brochure for buspi[INVESTIGATOR_226479] 
p450 degradation pathways.  
5.4 SCREEN FAILURES  
 
Screen failures are defined as participants who consent to participate in the clinical trial but are not subsequently 
randomly assigned to a study treatment group. A minimal set of  screen failure information is required to ensure 
transparent reporting of screen failure participants, to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements, and to respond to queries from regulatory authorities. Minimal  information 
includes demographics, reason for screen failure, and any serious adverse event (SAE). Screening failures also 
include participants who meet medical eligibility criteria but change their mind and do not consent to randomization 
into the trial.  We collect all of the above information on each screen failure using a case-report form keyed into the 
BESST database . 
 
Individuals who do not meet the criteria for participation in this trial (screen failure) because of a contraindicated 
medication or wh o is unable to complete all tests within the allotted screening window may be rescreened one 
time . A rescreened participant is  assigned the same participant number as for the initial screening.  
 
 
5.5 STRATEGIES FOR RECRUITMENT AND RETENTION  
5.5.1  RECRUITMENT  
Approximately 108 participants will be recruited from the six clinical centers of the GpCRC (averaging 18 participants 
per center) over a  30-month period. Participants will be recruited from outpatient clinics and inpatient hospi[INVESTIGATOR_226480].  
 
Potentially eligible participants will be identified and registered for screening at the participating clinical centers 
subject to the inclusion and exclusion criteria listed above. Eligible and consenting participants will be randomized to 
a treatment gro up after completion of all required screening procedures, keying of all required data elements into 
the data system, and passing eligibil ity checks for the BESST trial.  
 
Each clinical center will develop a specific recruitment plan. These plans will vary f rom clinic to clinic depending on 
the available pools of participants and local recruitment resources. Clinics will attempt to recruit sufficient overall 
BESST  Protocol #  [ADDRESS_272338] Protocol -  Version 1.3  Confidential, not for distribution  20 numbers of minorities and males since gastroparesis is reported to be rare in African-Americans and infrequent in 
men, so that the study results can be generalized to these sub -groups of the U.S. population . 
 
Participants may be reimbursed for travel expenses for each visit completed depending on each clinic’s resources.  
 
6 STUDY INTERVENTION 
 
6.1 STUDY INTERVENTION (S) ADMINISTRATION  
 
6.1.1  STUDY INTERVENTION DESCRIPTION  FROM FDA PACKAGE INSERT  
 
Buspi[INVESTIGATOR_226458], USP is an antianxiety agent that is not chemically or pharmacologically related to the benzodiazepi[INVESTIGATOR_1651], barbiturates, or other sedative /anxiolytic drugs. Buspi[INVESTIGATOR_226481] a white 
crystalline, water soluble compound with a molecular weight of 422.0. 
 
Chemically, buspi[INVESTIGATOR_226481] 8-[4-[4-(2-pyrimidinyl) -1pi[INVESTIGATOR_200270]]butyl]-8 -azaspi[INVESTIGATOR_2152][4.5]decane-  7,9-dione 
monohydrochloride. The empi[INVESTIGATOR_62497] C21H31N5O2 • HCl is represented by [CONTACT_226558]:  
 
 
 
The mechanism of action of buspi[INVESTIGATOR_226482]. Buspi[INVESTIGATOR_226483]. It also lacks the prominent sedative effect that is 
associated with more typi[INVESTIGATOR_226484]. In vitro preclinical studies have s hown that buspi[INVESTIGATOR_226485] a high affinity 
for serotonin (5 -HT 1a) receptors. Buspi[INVESTIGATOR_226486] γ-aminobutyric acid ( GABA ) binding in vitro or in vivo when tested in preclinical models.  
 
Buspi[INVESTIGATOR_226487] D2 -dopamine receptors. Some studies do suggest that buspi[INVESTIGATOR_226488]. Buspi[INVESTIGATOR_226489] s and undergoes 
extensive first -pass metabolism. In a ra diolabeled study, unchanged buspi[INVESTIGATOR_226490] 1% of the radioactivity in the plasma. Following oral administration, plasma concentrations of unchanged 
buspi[INVESTIGATOR_226491]. Peak plasma levels o f 1 ng/mL to 6 ng/mL have been 
observed 40 to 90 minutes after single oral doses of 20 mg. The single -dose bioavailability of unchanged buspi[INVESTIGATOR_226492] a tablet is on the average about 90% of an equivalent dose of solution, but there is large  varia bility.  
 The effects of food upon the bioavailability of buspi[INVESTIGATOR_226493]. They were given a 20 
mg dose with and without food; the area under the plasma concentration -time curve and peak plasma 
concentration (Cmax) of unchanged buspi[INVESTIGATOR_226494] 84% and 116%, respectively, but the total amount of 
buspi[INVESTIGATOR_226495]. This suggests that food may decrease the extent of 
presystemic clearance of buspi[INVESTIGATOR_5331].  
 
Buspi[INVESTIGATOR_131521] a [ADDRESS_272339] drugs predominantly used to treat anxiety, buspi[INVESTIGATOR_5331]'s pharmac ology is not related to benzodiazepi[INVESTIGATOR_226496] #  [ADDRESS_272340] including the stomach (66). Buspi[INVESTIGATOR_226475] [ADDRESS_272341] in both in vitro and in vivo experimental models using guinea pi[INVESTIGATOR_14107].  
 
6.1.2  DOSING AND ADMINISTRATION  
 
In this trial, a 10  mg buspi[INVESTIGATOR_226497] a size 0 gelatin capsule (approximately 2.2 cm) 
with partial filler , the inactive ingredients  being : colloidal silicon dioxide, lactose, magnesium stearate, 
microcrystalline cellulose, and sodium starch glycolate . The matching placebo capsule will contain only filler.  Each 
bottle contains [ADDRESS_272342] of a numbered study drug bottle; each bottle number will be unique and each participant will be assigned a specific bottle number. The bottle number issued by [CONTACT_226559] d bottles of study drugs which have been sent to the clinical 
center’s research pharmacy by [CONTACT_226560]’s GMP Research Pharmacy . Upon learning the bottle number to be issued 
to the specific participant, the research pharmacy will issue that bottle to the participant. Each participant’s 
random treatment assignment will be generated for that specific participant and will not be transferable to 
another participant. Once the assignment has been generated, the participant will be issued the study drug and 
instructe d about taking the study dug orally [ADDRESS_272343] the participant as follows : 
 
1. Do not take  a monoamine  oxidase inhibitor  (MAOI).  Ask your  healthcare provider  or pharmacist  if you are not 
sure if you take an MAOI, including the antibiotic  linezolid.  
2. Do not take an MAOI within [ADDRESS_272344] 2 weeks unless directed to do so by 
[CONTACT_226561].  
4. Inform your Primary Care Physician that you are participating in a randomized , control led trial comparing 
buspi[INVESTIGATOR_226498] (10  mg 3 times per day) and placebo.  
5. Inform you r physician and the study investigator about any prescription or non -prescription medications, 
prescription or non -prescription supplements, alcohol, or drugs that you are now taking or plan to take 
during your participation in BESST . 
6. Inform your  physician  if you are pregnant  or breastfeeding,  or if you are planning to become  pregnant,  or 
if you become pregnant while you are taking buspi[INVESTIGATOR_226458].  
7. Until you experience how this BESST study medication affects you, do not drive a car or operate  potentially 
dangerous machinery.   
8. During your treatment with BESST study medication , avoid  consumption of grapefruit juice or eating 
grapefruit, pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices until after the final dose.  
9. If you miss a dose of this medicine, take it as soon as possible unless it is almost time for your next dose, in 
which case, skip the missed dose and go back to the regular dosing schedule. Do not double doses. 
 
 
BESST  Protocol #  [ADDRESS_272345] Protocol -  Version 1.3  Confidential, not for distribution  22 6.2 PREPARATION/H ANDLING/ STORAGE/ ACCOUNTABILITY  
6.2.[ADDRESS_272346] 
(30 days after IND receipt by [CONTACT_8415]) or sooner if notified. After review by [CONTACT_1622], the use of buspi[INVESTIGATOR_226499] B ESST 
trial was given an IND exempt status. All masked drug and placebo bottles will be distributed to the individual 
GpCRC Clinical Centers ’ Investigational Pharmacies or responsible entities  by [CONTACT_226560]’s contracted GMP Drug 
Distribution Center  according to the directions of the SDRC. The GMP Drug Distribution Center will purchase the 
study drug (buspi[INVESTIGATOR_5331]) and the materials needed for manufacturing the placebo capsules , over -encapsulating the 
buspi[INVESTIGATOR_226500], manufacturing the microcrystalline  powder contained in the matching placebo capsule, 
encapsulating the placebo capsule, bottling the active and placebo capsules individually, label ing bottles according 
to the SDRC directions, and ship pi[INVESTIGATOR_226501]. Expi[INVESTIGATOR_226502] y drug will be disposed of 
by [CONTACT_226562].  
 
The local Investigational Pharmacy will provide the clinic investigator or coordinator with a masked BESST study 
drug bottle upon request after the participant’s randomization . The SDRC provides the bottle number to be 
requested from the local pharmacy  after the randomization request by [CONTACT_3652] . Participants wi ll be dispensed a 
bar-coded medication bottle as labeled by [CONTACT_226563]: “Buspi[INVESTIGATOR_5331] 10 mg or placebo. Take one 
capsule orally 3 times per day, 30 minutes prior to  meals.”  
 Participants  are instructed to take a single capsule of 10 mg buspi[CONTACT_119980] e or placebo three times a day, a pproximately 
30 minutes prior to meals.  
 Drug accountability information is maintained by [CONTACT_226564], the local  clinic investigational 
pharmacy, and in the study database for adjudication coordinated by [CONTACT_941] S DRC at the end of the trial or at any 
time during the trial, as needed.  
 
6.2.2  FORMULATION, APPEARANCE, PACKAGING, AND LABELING  
 
Buspi[INVESTIGATOR_226503]’s GMP Research Pharmacy, and then over -encapsulated in a gelatin capsule for oral administration.  
Half the capsules will contain 10 mg buspi[INVESTIGATOR_226498], USP (equivalent to 9.1 mg of buspi[INVESTIGATOR_226504], respectively).  The b uspi[INVESTIGATOR_226505]: colloidal silicon dioxide, 
lactose, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate . The other half of the 
gelatin capsules (placebo) will contain only the filler.  
 
6.2.[ADDRESS_272347] STORAGE AND S TABILITY 
 
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].  
Dispense in a tight, light -resistant container as defined in the USP, with a child -resistant closure (as required).  
 
6.2.[ADDRESS_272348]  Protocol #  [ADDRESS_272349] Protocol -  Version 1.3  Confidential, not for distribution  23  
6.3 MEASURES TO MINIMIZE BIAS : RANDOMIZATION  AND BLINDING  
 
Randomization:  The randomization scheme will assign participants in randomly permuted blocks of assignments 
stratified by [CONTACT_138554]. This scheme will ensure that the two groups will be of nearly equal size and will be 
balanced  by [CONTACT_226565]  (to 
minimize secular effects) and by [CONTACT_6903] (to minimize clinic effects ). 
 
The randomization plan will be prepared and administered centrally, using a secure web application,  by [CONTACT_226560] . 
An assignment will be issued  only if the trial database shows that the participant is eligible, has signed the consent 
statement, and has had all required baseline data keyed to the data system.  
 
Treatment assignments are double-masked throughout the stud y until all data collection for the BESST trial has 
been completed, i.e., after completion of the [ADDRESS_272350] -trial follo w-up visit for all participants . Every effort will 
be made to maintain the masking throughout the study except in emergency situations.  The randomization code 
masking the bottle contents  will not be provided by [CONTACT_226566] ’s 
principal investigator.  
 
Unmasking of study medication will occur under the following conditions:  
 
• Severe allergic reaction (Stevens -Johnson Syndrome) : Study medication is stopped indefinitely. The 
participant, primary care provider (PCP), and the investigator will be  unmasked.  
 
• Pregnancy during the study : Study medication will be stopped indefinitely, and the coded medication will 
be unmasked. The participant, PCP, and investigator will be notified of the assigned treatment and the 
associated risks of  teratogenicity.  
 
In unforeseen situations where the clinical center principal investigator [INVESTIGATOR_226506]’s health and well -being, unmasking may be done after notifying the Executive Committee. The 
Data and Safety Monitoring Board will review all instances of unmasking that have occur red. 
 
 
6.4 STUDY INTERVENTION COMPLIANCE  
 
Assessment of adherence to the assigned study drug will provide clinic staff a means to identify participants 
having problems with adherence. Adherence will be assessed by: 
• Counts of capsules in the participant’s returned medication  bottle  at the end of the trial  
• Conducting a brief, structured interview, in which the study coordinator will assist the participants to 
identify problems in taking t he study drug and to estimate adherence to the prescribed medicine since 
their previous  visit during the trial.  
These assessments will guide the consideration of strategies to improve adherence  and to assess adherence  at the 
end of the trial . 
  
BESST  Protocol #  [ADDRESS_272351] Protocol -  Version 1.3  Confidential, not for distribution  24  
6.5 CONCOMITANT THERAPY  
 
For this protocol, a prescription medication is defined as a medication that can be prescribed only by a properly 
authorized/licensed clinician. Medications to be reported in the Case Report Form s (CRF) are concomitant 
prescription medications, over -the-counter medications and supplements.  
 
Medication histories are collected at enrollment and at each follow -up visit.  The participant is requested to bring 
all medication  and supplement  bottles  (pres cription and non -prescription)  or a photo of each bottle to the clinic 
visit.   
 
The drug interaction/contraindication list from the buspi[INVESTIGATOR_226507] ’s drug label (package insert) will be 
the definitive source of identifying which concomitant pharmac euticals and herbal supplements should be 
considered in determining eligibility for this study and which medications can be safely taken with buspi[INVESTIGATOR_226508] .  
 
Medications known to interact with buspi[INVESTIGATOR_226498] (buspi[INVESTIGATOR_5331]) are excluded from use during the trial. 
These include:  
• MAO  inhibitors, such as phenelzine, linezolid, isocarboxazid, methylene blue, moclobemide, phenelzine, 
procarbazine, rasagiline, safinamide, selegiline, and tranylcypromine  
• The blood thinner warfarin (Coumadin)  
• Haloperidol  
• Benzodiazepi[INVESTIGATOR_1651]  
• Drugs used to treat seizures, such as phenytoin (Dilantin) and carbamazepi[INVESTIGATOR_050] (Tegretol)  
 
In addition, using buspi[INVESTIGATOR_226509]. 
These medications are s elective serotonin reuptake inhibitors (SSRIs)(e.g., fluoxetine, nefazodone and trazodone 
(Oleptro)), and tricyclic antidepressants (TCA; e.g., amitriptyline/nortriptyline, trazodone). Some drugs interact with 
buspi[INVESTIGATOR_226510], including azole antifungals (e.g., itraconazole, ketoconazole), some antibiotics (including erythromycin, ri fampin), nefazodone, cimetidine, ritonavir, diltiazem, verapamil, and 
certain anticonvulsants (e.g., phenytoin, phenobarbital).  
 
Drugs with the possibility of a serious adverse event or disruption of the clearance rate have been listed as 
exclusions to th e study.  The treating physician will assess each participant’s medication  profile both for study 
eligibility at screening and for ongoing safety during the trial, and participants will be excluded from randomization 
or have trial treatment discontinued on  a case -by-case basis per local clinical judgment.  
 
Participants will be questioned regarding any new medication s at each visit and counseled by [CONTACT_226567], unless they are medically necessary. The study physician will decide 
whether suspension of the study medication is indicated . 
 
 
6.5.[ADDRESS_272352]  Protocol #  [ADDRESS_272353] Protocol -  Version 1.3  Confidential, not for distribution  25 7 STUDY INTERVENTION DISCONTINUATION  AND PARTICIPANT  DISCONTINUATION /WITHDRAWAL  
 
Participants may withdraw voluntarily from the study or the PI [INVESTIGATOR_113961] , for cause,  discontinue a participant from the 
study. In addition, participants who discontinue the study medication  will be encouraged to remain in the study for 
follow -up purposes , especi ally for safety and efficacy study outcomes. Study medication discontinuation s and 
participant discontinuation s/withdrawal s from the study will be documented on case report forms, which capture the 
date s and the specific underlying reason s for discontinuat ions of study medications  or participant 
discontinuation s/withdraw als. 
 
7.1 DISCONTINUATION OF STUDY INTERVENTION  
 
If the participant develops a treatment -related CTCAE v5.0 -defined adverse event (grade 3 or above) on the 10  mg 
dose, the study medication will be stopped after assessment by [CONTACT_226568], who is a licensed 
physician. If in the view of the study investigator, the participant is intolerant of the medication, the participant 
will be withdrawn from the study medication,  but will continue to be followed to the end of the trial.  
 
Discontinuation from buspi[INVESTIGATOR_226511] --  all remaining study 
data should be completed as indicated by [CONTACT_4690]. If a clinically significa nt finding is identified after 
enrollment, the investigator or qualified designee will determine if any change in participant management is 
needed. If indicated, adverse event (AE) case report forms will be completed and entered into the study database.  
 
The data to be collected at the time of study intervention discontinuation will include the following:  
• Labs and  anthropometrics  at the prior visit or at the AE occurrence  
• Study medication bottle number s and documentation of capsule  counts  
 
7.2 PARTICIPANT  DISCONTINUATION /WITHDRAWAL  FROM THE STUDY  
 
Participants are free to withdraw from participation in the study at any time upon written request . 
 
An investigator may discontinue or withdraw a participant from the study for the following reasons:  
 
• Pregnancy  
• Significant study intervention non -compliance  
• If any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs 
such that continued participation in the study would not be in the best interest of the participant  
• Disease progression which requires discontinuation of the study  intervention  
• If the participant meets an exclusion criterion (either newly developed or not previously recognized) that 
precludes further study  participation  
• Participant is unable to receive buspi[INVESTIGATOR_163274] 7  days.  
• The sponsor or investigator terminates the study.  
 
 
If, during the trial,  a participant develops non -life threatening side -effects , the study medication will be suspended  
if the participant insists, after consultation with a study physician . If the participant decides to stop t he study  
medication,  the participant will still be followed in the trial according to the protocol, in keepi[INVESTIGATOR_226512] #  [ADDRESS_272354] be taken if a participant fails to return to the clinic for a required study visit:  
• The site will attempt to contact [CONTACT_62541] 7 days and counsel 
the participant on the importance of maintaining the assigned visit schedule and ascertain if the 
participant wishes to and/or should continue in the study.  
• Before a participant is deemed lost to follow -up, the investigator or designee will make every effort to 
regain contact [CONTACT_6635] (where possible, 3 telephone calls and, if necessary, a certified letter 
to the participant’s last known mailing ad dress or local equivalent methods). These contact [CONTACT_73758]’s medical record or private study  file, but will not be documented in 
the study database. 
• If the participant cannot be reached, the participant will be consid ered to have withdrawn from the study 
with a primary reason of lost to  follow -up. All study data collected prior to the lost to follow -up will be 
used . 
 
The occurrence of missing data in this trial is expected to be low and, when present, is expected to be  equally 
distributed across the [ADDRESS_272355] experience, that careful selection  and education  
of participants during the screening phase before the consent will  result in no more than 10% lost to follow -up 
before completing the  full [ADDRESS_272356] trial can be divided into 4 phases: 
• Screening for eligibility for enrollment ( up to 3  visits over 8 weeks)  
• Randomization to treatment (1 visit)  
• Treatment phase ( 3 visits over 4 weeks: 1 visit at 2 weeks and 2 visits at 4 -weeks)  
• Post -treatment washout phase (1 visit at 6 weeks)  
 
8.1.[ADDRESS_272357]  Protocol #  [ADDRESS_272358] Protocol -  Version 1.3  Confidential, not for distribution  27 visit and after confirmation that all of the participan t’s questions about the study have been answered.  Recording 
of screening data on GpCRC BESST forms may not start until the participant has signed the consent statement. 
Screening and baseline data collection procedures will include questionnaires  (see 8.1.5 ) (baseline medical history, 
HADS, SF-36v2, GSRS, PAGI -QOL, PHQ -15, PAGI -SYM, symptoms side effects) , physical examination and E CG, 
measurement of fasting complete blood count (CBC), comprehensive metabolic panel (CMP) , thyroid stimulating 
hormone ( TSH) and HbA1c, a Gastric Emptying Scintigraphy (GES) test, an Electrogastrogra m (EGG) with water 
load test  (on a separate day) , a pregnancy test (if female  of child -bearing potential ) and fasting blood collection 
for serum and plasma banking.  Prior therapy for gastroparesis and concomitant medications  will be reviewed as 
outlined in the inclusion and exclusion criteria. Patient charts will be reviewed for historical medical information 
and procedures. A diagnostic upper endoscopy or an upper GI radiographic series will be scheduled if the 
potential participant has not had this test with in the past two years . 
 
Once a potential participant has agreed and consented to participate in BESST, a Gastric Emptying Scintigraphy 
(GES) test will be scheduled. In addition, the preference is to schedule the Electrogastrogra m (EGG) with water 
load test within a week of the GES test.  Immediately prior to the GES test, f emales of childbearing potential must 
have a negative pregnancy test. For the GES test, the participant  will arrive at the clinic after an 8-hour fast, that is 
nothing by [CONTACT_226569] [ADDRESS_272359]. The  
PAGI -SYM questionnaire ( see section 8.1 .5a) will be completed and then the participant will undergo the GES test 
as described in section 8.[ADDRESS_272360].  
 
The potential  participant  will be given a set of the daily symptom diary (ANMS GCSI -DD) forms to complete each 
night at home. These are returned to the clinic  at their second clinic screening visit after 7- days have been 
completed.  
 
For the second screening visit, t he participant  will arrive at the clinic after an [ADDRESS_272361] web- based data base management  system has an application to check patient eligibility based 
on data forms keyed and verified into the study database.  The eligibility check application is used during screening 
a patient to show failed inclusion/exclusion eligibility checks , to show missing required data . Clinic staff can use 
this task to identify the items that still need to be completed,  keyed, or verified after data from the screening 
visits are keyed. To avoid inconvenience to potential participant s, the randomization application should not be 
attempted until the eligibility check application indicates that the patient is eligible except for the items that can  
only  be completed at the randomization  visit. 
 
8.1.[ADDRESS_272362] of generating the random study 
medication assignment and is the procedure which defines a participant’s  enrollment into the trial. Randomization 
can occur after eligibility has been fully checked and all data collected at the screening visits have been keyed to the 
trial database. Since these processes take time, randomization cannot be done at a screening v isit, and since study 
medication needs to be issued to the participant, the randomization visit must be completed in person with the 
participant. Therefore, a visit separate from the screening visits is necessary. Since this will be a visit on a different calendar day and medication will be started at this visit, good clinical practice requires that a few basic checks of the participant’s  well-being be completed at the randomization visit.  
BESST  Protocol #  [ADDRESS_272363] Protocol -  Version 1.3  Confidential, not for distribution  28  
The procedures completed at the randomization visit are: pregnancy test for females of child bearing potential, 
verification that the participant  is feeling well,  affirmation of consent , review of concomitant drugs and vital signs 
(systolic and diastolic blood pressure, heart rate, respi[INVESTIGATOR_697], body temperature). All  participants  will be given 
information on a healthy life style  and gastroparesis diet , and instructions on when to take their drug, and 
information to be aware of while taking busp irone (see section 6.1.2). A set of daily -dairy forms will be distributed to 
the participant to complete each day and return to the clinic at their week [ADDRESS_272364] an interval of time surrounding the ideal date for the visit during which the visit may be done and the data included in the trial database. The ideal date for the week 2 visit is t he 
randomization date plus 2 weeks (14 days); the ideal date for the week 4 visit is the randomization date plus 4 weeks (28 days). Visit windows will be constructed to be contiguous, so that at any point in time, some visit window is 
open, subject to a ch eck on the minimum separation of at least one week between consecutive visits. The specific 
assessments and procedures required at each of the follow -up visits are:  
 
• Week 2 : pregnancy test for females of child bearing potential, follow -up medical history with review of adverse 
events, concomitant medications and study adherence, assessment of vital signs (systolic and diastolic blood 
pressure, heart rate, respi[INVESTIGATOR_697], bo dy temperature), and the following surveys: Hospi[INVESTIGATOR_226513] (HADS) , PAGI -SYM, and the Clinical Patient Grading Assessment Scale (CPGAS)( see section 8.1 .5) 
and a symptoms side-effect questionna ire (see section 8.2 for details). In addition, the participant  will return 
their Daily-Diary forms and receive another set to complete for return at the Week 4 visit.  
 
• Week 4:  the week [ADDRESS_272365]. Informati on to be collected at this visit includes: pregnancy test for 
females of child-bearing potential, a GES test, follow -up medical history with review of adverse events 
and concomitant medications, physical exam and E CG, fasting blood draw for CMP  and CBC , review of 
adherence and the following surveys: HADS, SF-36v2 Quality of Life, PAGI -SYM, GSRS, PAGI -QOL, PHQ -
15, symptom side-effects, and the CPGAS.  Fasting b lood will be drawn for serum and plasma banking. In 
addition, the participant will return their d aily-diary forms and receive one more set of daily- diary forms 
to complete each night to return at their [ADDRESS_272366] will be  undergone  the morning of the following da y or as soon as can 
be possibly scheduled within the v isit window. The participant will wait and take their buspi[INVESTIGATOR_226514] 15  
minutes  prior to the EGG baseline recording. The participant will return all bottles of the study drug 
dispensed  to the clinic staff .  The participant will be instructed to not take an y more drug after this visit.  
 
• Week 6:  At this visit, the participant will return their final set of daily -diary forms. Information to be collected 
includes: the follow -up medical history form with review of adverse events and concomitant medications, 
physical exam and fasting blood draw for CMP, CBC, and for banking plasma and serum with the NIDDK 
Biorepository, and the following questionnaires: HADS, PAGI -SYM, GSRS, PAGI -QOL, symptom side-effects, 
CPGAS.  A BESST study close -out form will document the participant’s end of participation in BESST.  
8.1.[ADDRESS_272367]  Protocol #  [ADDRESS_272368] Protocol -  Version 1.3  Confidential, not for distribution  29 Standardized questionnaires to assess efficacy:  
Several standardized questionnaires will be administered to participants enrolled in t he BESST trial. 
Questionnaires will be administered at baseline (prior to randomization) and during follow -up at specified 
intervals (see 1.3  for the Schedule of Activities ). The purpose of the questionnaires is t o obtain information 
regarding gastroparesis symptoms, side effects, and health -related quality of life.  
 
a. The Patient Assessment of Upper GI Symptoms (PAGI -SYM)  assesses the severity of symptoms of 
gastroparesis, functional dyspepsia, and gastroesophageal reflux disease [24] . The scale assesses symptoms over 
the prior two weeks, graded by [CONTACT_226570] (0) to very severe (5). It includes the nine symp toms of 
the Gastroparesis Cardinal Symptom Index (GCSI), a validated patient -reported outcome  (PRO) for gastroparesis 
using a two -week recall period. The nine symptom GCSI (nausea, vomiting, retching, stomach fullness, unable to 
finish a meal, feeling exce ssively full after meals, loss of appetite, bloating, belly visibly larger) is based on three 
subscales (postprandial fullness/early satiety, nausea/vomiting, and bloating) [25]. The PAGI- SYM also includes 
upper abdominal pain, which will be used for this study. The PAGI- SYM is in the public domain for use by 
[CONTACT_226571] . 
 
b. ANMS GCSI -DD is a daily dairy developed by [CONTACT_226572] (ANMS) 
for gastroparesis [26] . The ANMS GCSI-DD is undergoing qualifica tion by [CONTACT_226573] a pa tient-reported 
outcome (PRO) outcome for clinical trials evaluating new treatments for either diabetic or idiopathic gastroparesis  
[27]. The ANMS GCSI -DD consists of five core symptoms (nausea, vomiting, early satiety, postpr andial fullness, 
upper abdominal pain). Each night, participants grade the  severity of symptoms over the prior 24 hours. The 
ANMS GCSI -DD core symptom composite score (an average of the five core symptoms) is designed to detect 
clinical improvement in symptoms of gastroparesis and to be used as a PRO outcome for clinical  trials.  
c. Clinical Patient Grading Assessment Scale (CPGAS) will be used to help assess the therapeutic response of the 
participants. Participants will be asked if their rating of relief of symptoms during the past week compared to the 
way the participant  usually f eels has improved, stayed the same, or worsened with study treatment. The clinical 
response of their gastroparesis symptoms to study treatment with one point gradations from (+7) = completely 
better; (0) = no change, and ( -7) = very considerably worse. Res ponders are defined as those with score of > 0 and 
non-responders with score of < 0 by [CONTACT_226574]  [28]. 
 
d. Health Survey (SF -36v2)  is a 36 -item, self -report measure designed to assess quality of life in participants  [29]. 
This measure also provides two summary scores (physical and mental health) and eight scale scores. It is reliable 
and internally  consistent.  A higher summary score indicates better quality of life.  
 
e. Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI -QOL)  is a self -completed 
disease -specific quality of life questionnaire; the respondent scores each of 30 factors  from 0 (none of the time) to 
5 (all of the time) [30] . Items cover how often gastrointestinal problems have affected different aspects of their 
quality of life and well- being in the past two weeks.  There are five domains: Daily Activities, Clothing, Diet and 
Food Habits, Relationship, and Psychological Well-Being and Distress. Overall PAGI -QOL scores are  calculated by 
[CONTACT_226575]; thus a mean PAGI -QOL score of [ADDRESS_272369] life  quality.  
 
h. The Hospi[INVESTIGATOR_5620] (HADS) [31]  was developed by [CONTACT_226576] (1983) and is 
commonly used to determine the levels of anxiety and depression that a patient is experiencing. The HADS is a fourteen-item scale that generates ordinal data. The HADS is comprised of 2 subscores, each sco red from 0-21 
points: HADS -A is the anxiety subscore and HADS -D is the depression subscore.  Each subscore includes 7 
questions which are each scored from 0 (not at all) to 3 (most of the time). The items for each subscore are 
summed and the average result s in the subscore.  
 
BESST  Protocol #  [ADDRESS_272370] Protocol -  Version 1.3  Confidential, not for distribution  30 g. The Gastrointestinal Symptoms Rating Scale (GSRS) is a clinical rating scale for gastrointestinal symptoms in 
participants with irritable bowel syndrome and peptic ulcer disease [32]. There are 15 items on the instrument, 
which are scored on a 7 -point Likert scale from 0=no discomfort to 7=very severe. Using the scoring manual, total 
score and 5 scales can be computed (Abdominal pain, Reflux syndrome, Diarrhea syndrome, Indigestion 
syndrome, Constipation  syndrome).  
 
h. The Patient Health Questionnaire  15 Somatic Symptom Severity Scale  (PHQ -15) [33] is a brief, self -
administered questionnaire that may be useful in screening for somatization and in monitoring somatic symptom 
severity in clinical practice and research.  The total PHQ -[ADDRESS_272371] 4 weeks rated in severity from 0 (not bothered at all) to 2 (bothered a lot).  
 
8.1.6  STUDY PROCEDURES  
Tests to assess efficacy:  
Gastric Emptying Scintigraphy (GES)  
Gastric emptying scintigraphy will be performed using a low -fat, egg white Eggbeaters®meal with imaging at 0, 1, 
2, 4 hours after meal ingestion, as endorsed by [CONTACT_226577] (ANMS) (3 4,35). This protocol ensures standar dized information 
about gastric emptying across multiple sites. Participants are instructed to come to the Nuclear Medicine Section 
in the morning after an [ADDRESS_272372], with appropriate treatment measures being taken if low blood sugar 
(hypoglycemia or glucose < 60 mg/dL) or high blood sugar (hyper glycemia or glucose >270 mg/dl) is detected. GES 
is performed using a standard low -fat, egg -white Eggbeaters®meal to measure solid emptying. The meal consists 
of the equivalent of two large eggs radiolabeled with 0.5 -1 mCi Tc -99m sulfur colloid served with two pi[INVESTIGATOR_226515]. Participants are given 120 ml water . Following ingestion of the meal, imaging is performed 
at 0, 1, 2 and 4 hrs with the participant upright for measuring gastric emptying of Tc -labeled solids. In between 
imaging, part icipants  generally sit in the nuclear medicine waiting area. Symptoms (nausea, fullness, pain severity, 
and epi[INVESTIGATOR_114128]) will be monitored and recorded during the GES test. Gastric emptying is analyzed as 
percent of radioactivity retained in the stomach over time using the geometric center of the decay-corr ected 
anterior and posterior counts for each time point. Gastric retention of Tc-99m >60 % at 2- hours and/or >10% at 4-
hours is considered delayed gastric emptying of solids. Delayed gastric emptying is graded according to the gastric 
retention at 4 -hours:  mild (≤20% gastric retention at 4 hours), moderate (>20 to 35%), and severe (>35%)  [35]. 
 
Intragastric meal distribution  (IMD) , as an assessment of fundic accommodation  (FA), during GES .  
Analysis of regional intragastric meal distribution will be perform ed of the digital archived gastric emptying 
images, both at baseline and at the 4 -week visit. We will use a modification of the  method reported by [CONTACT_25715][INVESTIGATOR_223671], 
Tack, et al to assess intragastric meal distribution [14]. We will use our semi -automated analysis of regional 
intragastric meal distribution during GES. The analysis begins by [CONTACT_226578], then drawing regions of 
interest around the stomach using thresholding. The longitudinal axis of the stomach is then constructed. The 
stomach is then divided into two (proximal, distal) regions of interest by [CONTACT_226579]. The amount of radioactivity  in each gastric region will be expressed as a percent of the total amount of 
radioactivity in the stomach at time 0. This will be assessed over time. The ratio of proximal over distal counts will 
be computed for each time period (0, 1, 2, 4 hours). The amount in the proximal region of interest at time [ADDRESS_272373]  Protocol #  [ADDRESS_272374] Protocol -  Version 1.3  Confidential, not for distribution  31 provides a measure of fundic accommodation. Impaired fundic accommodation using IMD is <0.568 ratio of the 
proximal gastric counts to the total gastric counts.  
 
Electrogastrogram ( EGG ) with water load satie ty test  [36]: 
For each EGG and water load test, the clinical center needs to have a one -liter opaque cup for water, [ADDRESS_272375], that is nothing by [CONTACT_226580]. Participants may take their usual medications with a small amount 
of water (up to 4 ounces ) up to two hours prior to the study, but should refrain from coffee, tea, or juice. After 
arrivi ng at the clinic, diabetic participants’ blood glucose level will be checked to ensure it is less than 270 mg/dL. 
If the participant’s blood glucose level is greater than 270 mg/dL, it is either treated and rechecked before 
proceeding or the EGG and water load satiety test will be rescheduled for another day under better glucose 
control. The participant will take their buspi[INVESTIGATOR_226516] [ADDRESS_272376] will mark each symptom scale  with a vertical line to 
indicate how they currently feel in terms of that symptom’s severity  on a score from 0 (no sympto ms) to 100 (the 
most severe symptoms). Once the EGG and respi[INVESTIGATOR_226517], the baseline EGG recording period can 
begin. Participants will undergo a [ADDRESS_272377], participants will drink cool water from the 1 -liter cup. They will drink for a 5 -minute period until they feel 
"completely full ." It is important that the research associate at each site gives every participant the same 
instructions as follows:  
 
“I want you to drink water from this container until you feel completely full.   You have up to 
five minutes  to reach the feeling of being  complete ly full.  You may stop at any time, up to the 
five-minute time limit, when you feel completely full.  This is not at test to see how much you 
can drink, but to drink until you feel you are completely full  in the five-minute period.  Do you 
have any questio ns about this?”   
 
The total volume of water consumed  in mL  will be recorded.  
 
A continuous 30 -minute EGG recording is then obtained. The participant's symptoms are recorded using a visual 
analog scale  at 10, 20, and 30 minutes after ingestion of the water (at the end of the 0-10 minute, 11-20 minute, 
and the 21 -30 minute periods after the water loa d ingestion (post -satiety periods)). The test is completed after 
the [ADDRESS_272378]  Protocol #  [ADDRESS_272379] Protocol -  Version 1.3  Confidential, not for distribution  32 8.2 SAFETY AND OTHER ASSESSMENT S 
 
Assessments for Safety  
 
• Physical examination (e.g., height, weight, waist measurements, vital signs (temperature, heart rate, respi[INVESTIGATOR_862], blood pressure,  ECG).  
• Laboratory results –  All labs including creatinine, ALT, and glucose will be monitored at sites and in the central 
database and all abnormal values will be managed by [CONTACT_6962]. If the ALT, creatinine, or glucose levels 
are elevated, that measure  will be repeated within 5 days. If necessary, the participant will be give n management 
advice and information will be provided to the participant’s  PCP.  
 
• Standardized Questionnaires:  
a. Symptom side effects : Participants will be asked if they experienced any side effects from the BESST drug 
treatment and to describe any side effects. The baseline and follow -up medical histories will inquire about 
symptoms that may be attributed as side effects of buspi[INVESTIGATOR_226518] a standard set of questions. These 
symptoms include:  headache,  dizziness, tiredness, drowsiness,  sleep problems (insomnia) , nausea, upset 
stomach, blurred vision , nervousness or  excitement.  
b. Adverse Event Report form : This form will document occurrence  of an adverse event that threatens the 
integrity of the BESST trial or the well-being of a study participant during the trial. 
c. Serious Adverse Event/IND Safety Report : This form will document occurrence of any event reported on 
the Adverse Event Report fo rm that satisfies the FDA expedited IND Safety Report requirement.  
 
• Biological specimen collection and laboratory evaluations are included in the Schedule of Activities and section 
in 12.2. Instructions for the preparation, handling, storage, and shipment of specimens are detai led in the BESST 
Standard Operating Procedures manual . 
 
If a participant has scores on the psychological questionnaire indicating significant a nxiety or depression (HADS-A 
≥ 15  and/or HADS -D ≥ 15 indicating severe symptoms) or by [CONTACT_15370]’s assessment , the clinical center 
investigator or staff will suggest that they see a clinical psychologist or psychiatrist and information on these 
referrals will be given to the participant  [37].  If the clinician is concerned that a participant is actively suicidal or at 
risk of self -harm, the clinical center investigator will help make arrangements for them to be seen that day for 
further assessment . 
 
For a ssessment of study intervention adherence see Study Intervention Compliance, section 6.4 . 
 Management of Comorbid Conditions  
 
Any participant’s  comorbid conditions, including diabetes, will be managed according to the best clinical practice 
or evidence -based practices by [CONTACT_16541] [INVESTIGATOR_226519]’s primary care 
physician ( PCP) , and with consideration for medi cations contraindicated for use with buspi[INVESTIGATOR_5331] (listed in section 
6.5).  Most of the comorbid conditions will be treated by [CONTACT_226581] ’s regular physicians ; worsening of the condition  will be  treated by [CONTACT_978] [INVESTIGATOR_226520]’s r egular physicians. If the physician determines that the participant’s safety is 
at risk, the participant’s study drug will be discontinued.  For follow -up care, the physician will refer the 
participant to their PCP or a specialist, if needed, and also continue to follow  the participant  at the site.  
 
A uniform set of practices to be applied by [CONTACT_226582] i n the trial SOP ( Standard of Care document ), prepared by [CONTACT_226583], including the 
BESST  Protocol #  [ADDRESS_272380] 
clinical practice and guidelines from the American Gastroenterological Association, the American 
Neurogastroenterology and  Motility Society, and the American College of Gastroenterology .  
 If a participant develops diabetes during the participant’s participation in the trial and the physician determines 
the need for antidiabetic medication (e.g.,  because of lack of response t o life style changes), the use of 
medications not contraindicated with buspi[INVESTIGATOR_226521].  Likewise, for other classes of drugs (anti -hypertensives  or anti -depressants) that may be prescribed for a worsening comorbid 
condition, careful consideration must be given to whether there is a non- contraindicated treatment with 
buspi[INVESTIGATOR_226522], with the ultimate decision be ing the participant’s safety.  
 
Pregnancy will be  managed according to the guidelines and study drug will be discontinued immediately upon 
discovery. For safety, a pregnancy test is done for female participants  of child- bearing potential  at each follow -up 
visit and before each  GES procedure.  In the event of major dermatological reactions such as generalized urticaria, 
bullous rashes, and exfoliative dermatitis, study drug will be discontinued immediately and not restarted. For local 
skin reactions, study dr ug may be discontinued if the skin reactions are potentially drug related. If the rashes clear, 
the study drug may be restarted.  
 
Monitoring for comorbid conditions is done at each study visit through a follow -up medical history, follow -up 
physical exam, f ollow -up adverse event reports , and laboratory measures of glucose  or other labs , as well as 
assessments of vital signs.  
 In addition to the medications listed in section 6.[ADDRESS_272381] trial, the 
Buspi[INVESTIGATOR_226523]’s Brochure does not recommend use of the drug in patients with impaired 
hepatic or renal function. Prospective participants with these condition s will be excluded from the 
trial.  M ost adverse events reported while taking buspi[INVESTIGATOR_226524], and are 
unexpected in the [ADDRESS_272382] trial.  
  
 
Follow -up of Ongoing Adverse Events  
 
Provisions for follow -up of adverse events (AE) include phone calls by [CONTACT_226584], in -person follow up exams when needed to assess vital signs and physical findings and 
referral to local ongoing care by [CONTACT_226585][INVESTIGATOR_226525].  
 
The participant  is queried about the adverse event until there has been a resolution of the AE.  All information is 
recorded on the Adverse Event Report form and reviewed by [CONTACT_226586] a year or at more frequent intervals if  
the DSMB determines t he need.  In addition, any AE  with a severity grade greater than [ADDRESS_272383] 
Medical Safety Officer as soon as the event is keyed to the data system.  
 
8.3 ADVERSE EVENTS AND S ERIOUS ADVERSE EVENTS  
8.3.1  DEFINITION OF ADVERSE EVENTS  (AE)  
 
Adverse event means any untoward medical occurrence associated with the use of a drug in humans, whether or not 
considered drug related (21 CFR 312.32 (a)).  
 
8.3.2  DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)  
 
BESST  Protocol #  [ADDRESS_272384] Protocol -  Version 1.3  Confidential, not for distribution  34 An adverse event or suspected adverse reaction is considered "serious" if, in the view of either the investigator or 
sponsor, it results in any of the following outcomes: death , a life -threatening adverse event, inpatient hospi[INVESTIGATOR_226526], a persistent or significant incapa city or substantial disruption of the ability 
to conduct normal life functions, or a congenital anomaly/birth defect. Important medical events that may not result in 
death, be life -threatening, or require hospi[INVESTIGATOR_708], bas ed upon appropriate medical 
judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring int ensive 
treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient 
hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  
 
8.3.3  CLASSIFICATION OF AN ADVERSE E VENT  
 
The National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE)  version 5.0 will be used to 
classify Adverse Events when possible.  
[IP_ADDRESS]  SEVERITY OF EVENT  
 
All Adverse Events (AEs) will be assessed by [CONTACT_226587]’s Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 when possible. 
The GpCRC Medical Safety Officer  was involved in deciding which grading system to use for the GpCRC . 
 
For AEs not included in the protocol defined grading system, the following guidelines will be used to describe 
severity.  
 
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily activities.  
• Moderate – Events result in a low level of inconvenience or concern with the therapeutic measures. 
Moderate events may cause some interference with functioning.  
• Severe – Events interrupt a participant’s usual daily activity and may require systemic drug therapy or 
other treatment. Severe events are usually potentially life -threatening or incapacitating. Of note, the term 
“severe” does not necessarily equate to  “serious”.  
 
[IP_ADDRESS]  RELATIONSHIP TO STU DY INTERVENTION  
 
All adverse events (AEs) must have their relationship to study intervention assessed by [CONTACT_21217]/her clinical judgment.  
 
The degree of certainty about causality will be  graded using the categories below. In a clinical trial, the study 
product must always be suspect.  
 
• Definitely Related – There is clear evidence to suggest a causal relationship, and other possible 
contributing factors can be ruled out. The clinical event,  including an abnormal laboratory test result, 
occurs in a plausible time relationship to study intervention administration and cannot be explained by [CONTACT_9153]. The response to withdrawal of the study intervention 
(dec hallenge) should be clinically plausible. The event must be pharmacologically or phenomenological  
definitive, with use of a satisfactory rechallenge procedure if  necessary.  
• Probably Related –  There is evidence to suggest a causal relationship, and the influence of other factors is 
unlikely. The clinical event, including an abnormal laboratory test result, occurs within a reasonable time after administration of the study intervention, is unlik ely to be attributed to concurrent disease or other 
BESST  Protocol #  [ADDRESS_272385] Protocol -  Version 1.3  Confidential, not for distribution  35 drugs or chemicals, and follows a clinically reasonable response on withdrawal (dechallenge). Rechallenge 
information is not required to fulfill this  definition.  
• Potentially Related – There is some evidence to suggest a causal relationship (e.g., the event occurred 
within a reasonable time after administration of the trial medication). However, other factors may have 
contributed to the event (e.g., the participant’s clinical condition, other concomitant ev ents). Although an 
AE may rate only as “possibly related” soon after discovery, it can be flagged as requiring more 
information and later be upgraded to “probably related” or “definitely related”, as  appropriate.  
• Unlikely to be related – A clinical event, including an abnormal laboratory test result, whose temporal 
relationship to study intervention administration makes a causal relationship improbable (e.g., the event 
did not occur within a reasonable time after administration of the study intervention) and in which other 
drugs or chemicals or underlying disease provides plausible explanations (e.g., the participant’s clinical 
condition, other concomitant  treatments). 
• Not Related –  The AE is completely independent of study intervention administration, and/o r evidence 
exists that the event is definitely related to another etiology. There must be an alternative, definitive 
etiology documented by [CONTACT_15370].  
 
 
[IP_ADDRESS]  EXPECTEDNESS  
 
The Study Physician will be responsible for determining whether an AE is expected or unexpected. An AE is 
considered "unexpected" if it is not listed in the I nvestigator Brochure or is not listed at the specificity or severity 
that has been observed; "unexpected," as used in this definition, also refers to AEs or suspected adverse reactions that are mentioned in the Investigator Brochure as occurring with a class of drugs or as ant icipated from the 
pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug 
under investigation . 
8.3.4  TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
 
The occurrence of an AE or serious adverse  event (SAE) may come to the attention of study personnel during 
study visits and interviews of a study participant presenting for medical care, or upon review by a study monitor . 
 
All AEs including local and systemic reactions not meeting the criteria for  SAEs will be captured on the appropriate 
case report form. Information to be collected includes event description, time of onset, clinician’s assessment of 
severity, relationship to study product (assessed only by [CONTACT_8703] a 
diagnosis), and time of resolution/stabilization of the event. All AEs occurring while in the study must be documented appropriately regardless of relationship. All AEs will be followed to adequate resolution.  
 
Any medical condition that is present at the time that the participant is screened will be considered as baseline and not reported as an AE unless the AE results from a study procedure performed during screening. However, if 
the study participant’s condition deteriorates at any time during the study, it will be recorded as an AE.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each 
level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration of each epi[INVESTIGATOR_1865].  
 
The Study Physician and Clinical Coordinator will record all reportable events with start dates occurring any time after informed consent is obtained until 7 (for non -serious AEs) or 30 days (for SAEs) after the last day of s tudy 
participation. At each study visit, the investigator will inquire about the occurrence of AE/SAEs since the last visit. Events will be followed for outcome information until resolution or stabilization.  
BESST  Protocol #  [ADDRESS_272386] Trial will monitor and report adverse events to ensure participant safety. There are two separate 
sets of government regulations that apply to unanticipated or adverse events in research studies: (1) 45 CFR Part 46, 
Subpart A : the Common Rule,42 shared by 17 Departments and Agencies and ( 2) 21 CFR 312,41: the FDA regulation for 
adverse events. The Common Rule requires written procedures and policies for ensuring reporting of unanticipated 
problems involving risks to participants to IRBs, appropriate institu tional officials, and the Department or Agency Head. 
The FDA regulation requires notification of the FDA and participating investigators of any adverse event associated 
with the use of a test article that is both serious and unexpected. Investigators shoul d refer to the [ADDRESS_272387] Trial definitions and procedures for adverse events are designed to satisfy both sets of requirements.  
 
Adverse events will be recorded on the Adverse Event data forms whether or not they are thought to be associated 
with the study or with the study drug. Adverse events may be discovered during regularly scheduled visits or through 
unscheduled participant contacts between visits. Summary data on adverse events will be monitored by [CONTACT_226588] -annual meetings or more fr equently, as needed. These summaries will include analyses 
comparing rates of adverse events by [CONTACT_1570], by [CONTACT_6903], or in other subgroups requested by [CONTACT_4318]. Where 
applicable, signs and symptoms associated with the adverse event will be graded as to severity by [CONTACT_226589], moderate, or severe using the Common Terminology Criteria for Adverse Events  version  CTCAE v5.0 . 
 After each meeting, the DSMB will issue a written summary of its review of the study data, including adverse  events, 
for transmission to the IRBs at each of the study centers. Analyses or listings of adverse events will not be provided to 
the IRBs; however, adverse events involving unanticipated problems involving risks to participants, or breaches of 
protocol w hich might entail risk to participants must be reported to local IRBs as soon as possible after they are 
discovered. Each participating center is responsible for ensuring that all local IRB requirements for reporting adverse events are met. A summary of ad verse events will be reported to the FDA as part of the IND annual report.  
 
8.3.6  SERIOUS ADVERSE EVENT REPORTING  
  
Serious adverse events (SAE) must be reported upon discovery at the clinical center per local IRB guidelines. This will involve completing an Adverse Event (AE) data form describing the severity and details of the serious adverse 
event. This must be submit ted to the SDRC within one business day for review  by [CONTACT_183291]. If the 
serious adverse event is judged by [CONTACT_226590] a reasonable possibility of being 
caused by [CONTACT_226591][INVESTIGATOR_226527] , then the investigator must also submit to the SDRC a SAE/IND Safety Report 
(SR) form, along with a narrative summarizing the circumstances of the event, the current statu s of the 
participant, and a copy of the IRB report within two working days. The SDRC will submit a preliminary report to 
the NIDDK for review within three calendar days of receiving the SAE/IND Safety Report (SR) form. The 
pharmaceutical manufacturer will be notified within one working day but no longer than three calendar days of all 
fatal/life threatening serious adverse events, regardless of association to study drug,  
 
If NIDDK determines that the SAE requires an expedited IND Safety Report, the NIDDK Pr ogram Official or the 
NIDDK Regulatory Affairs Specialist will notify the FDA no more than 15 calendar days from the initial receipt of 
the SAE by [CONTACT_226560] (no later than 7 calendar days if the SAE is fatal or life threatening). The clinical center 
investigator may also be responsible for completing an FDA MedWatch [ADDRESS_272388]  Protocol #  [ADDRESS_272389] submit to the NIDDK and to the Scientific Data Research Center a follow -up memo within one month of the SAE (and periodic updates if needed) to report th e details of the 
disposition of the SAE.  
 
The SDRC will provide to the pharmaceutical manufacturer copi[INVESTIGATOR_226528], congenital anomaly/birth defects/fetal losses, hospi[INVESTIGATOR_059] s, and 
important medical events, such as cancers with no prior history  within five calendar days of receipt. In addition, 
the SDRC will report any pregnancy occurring in association with the use of study drug to the pharmaceutical 
manufacturer within three calendar days. The SDRC will report overdoses of the b uspi[INVESTIGATOR_226529]. An overdose that results in an SAE or is associated with an SAE, will follow the normal SAE reporting process and timeframe.  
 
8.3.7  REPORTING EVENT S TO PARTICIPANTS  
N/A 
 
8.3.[ADDRESS_272390]  
N/A 
 
8.3.[ADDRESS_272391] is obtained 
at study enrollment and at each visit to help assure that the participant is not pregnant. If a participant is found to 
be pregnant, study medication will be stopped indefinitely, and the coded medication will be unmasked. The 
participant, PCP, an d investigator will be notified of the assigned treatment and the associated risks.  
 
8.4 UNANTICIPATED PROBLEMS  
8.4.1  DEFINITION OF U NANTICIPATED PROBLEMS (UP)  
 
The Office for Human Research Protections (OHRP) considers unanticipated problems involving risks to part icipants 
or others to include, in general, any incident, experience, or outcome that meets all  of the following criteria: 
 
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are 
described in the IRB -approved resear ch protocol and informed consent document ; and (b) the 
characteristics of the participant population being  studied;  
• Related or possibly related to participation in the research (“possibly related” means there is a reasonable 
possibility that the incident, experience, or outcome may have been caused by [CONTACT_226592]); and 
• Suggests that the research places participants or others at a greater risk of harm (including physical, 
psychological, economic, or social harm) than was previously known or  recognized.   
BESST  Protocol #  [ADDRESS_272392] Protocol -  Version 1.3  Confidential, not for distribution  38  
8.4.2   UNANTICIPATED PROBLEM REPORTING  
 
The investigator will report unanticipated problems (UPs) to the reviewing IRB and to the SDRC/principal investigator 
(PI). The UP report will include the following information:  
 
• Prot ocol identifying information: protocol title and number, PI’s name, and the IRB project number;  
• A detailed description of the event, incident, experience, or  outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outc ome represents 
an UP; 
• A description of any changes to the protocol or other corrective actions that have been taken or are 
proposed in response to the UP. 
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:  
 
• UPs that are serious adverse events (SAEs) must  be reported to the IRB and to the SDRC/study sponsor  
within one working day from the date the investigator was aware  of the  event.  
• All other UP will be reported to the IRB and to the DCC/study spon sor within 10 days of the investigator 
becoming aware of the problem.  
• All UPs should be reported to appropriate institutional officials (as required by [CONTACT_17347]’s written 
reporting procedures), the supporting agency head (or designee), and the Office for Human Research 
Protections within 10 days  of the IRB’s receipt of the report of th e problem from the investigator. 
• Reports should be sent to:  [EMAIL_4472]   
• All timelines related to SAE reporting with details are provided in protocol section 8.3.6.  
 
8.4.[ADDRESS_272393] a greater risk 
of harm to participants.  
 
9 STATISTICA L CONSIDERATIONS   
9.1 STATISTICAL HYPOTHESES  
• Primary Efficacy Hypothesis : Buspi[INVESTIGATOR_226530] 10 mg three times daily for 4 weeks is better than placebo in 
improving early satiety and postprandial fullness in adults with symptoms of gastroparesis measured as 
change in the PAGI -SYM postprandial fullness/ea rly satiety subscore . 
 
• Secondary Efficacy Hypotheses : Buspi[INVESTIGATOR_226530] 10 mg three times daily for 4 weeks is better than placebo in 
improving the following outcomes : 
1. Changes  in GCSI total  score  
2. Changes  in PAGI -SYM subscores: nausea/vomiting, bloating, upper abdominal  pain, GERD  
3. Changes  in PAGI -SYM severity scores: Nausea, stomach fullness, inability to finish   a normal -
sized meal, feeling excessively full after meals, loss of appetite, bloating, upper abdominal  
pain  
4. Changes  in Gastrointestinal Symptom Rating Scale (GSRS) total  score  
5. Changes  in Clinical Patient Grading Assessment Scale (CPGAS)  score  
6. Changes  in PAGI -QOL total  score  
7. Changes  in the Hospi[INVESTIGATOR_5620] (HADS) total scores for anxiety and  
depression 
BESST  Protocol #  [ADDRESS_272394] Protocol -  Version 1.3  Confidential, not for distribution  39 8. Changes  in Patient Health Questionnaire (PHQ -15) total  somatization score  
9. Changes  in the SF-36v2 Quality of Life questionnaire physical and mental  components  scores  
10. Changes  in percent of gastric emptying  retention  
  
 
9.2 SAMPLE SIZE  DETERMINATION  
Summary of sample size and computation of primary outcome:  
The primary outcome  variable is change in the PAGI- SYM postprandial fullness/early satiety subscore from 
baseline to 4 weeks . This subscore is calculated by [CONTACT_226546] 4 PAGI -SYM items: stomach fullness, 
inability to finish a normal -sized meal, feeling excessiv ely full after meals, and loss of appetite.  Each item score 
ranges from 0 (none) to 5 (very severe) on an ordinal scale. The 4 -item average is treated as continuous  in the 
primary ANCOVA analysis of change and for sample size purposes. 
The planned 108 part icipants sample size for this trial was derived using the following assumptions and methods : 
• 2 equal size  groups  
• Power=90% 
• Type 1 error (2-sided) =  0.05  
• Two -sided tests  
• Sample size increased by 10% to allow for 10% loss in primary outcome  measure 
• Placebo group assumptions: Based on the APRON RCT placebo data  [9], we assumed that : 
o Mean (SD) change in postprandial fullness/early satiety subscore at 4 -weeks = 3.7  (0.8)  
o Change from baseline at 4 -weeks of fullness/early satiety subscore = -0.7 (1.0)  
o Correlation of postprandial fullness/early satiety subscore at baseline and 4 -weeks = 
0.55 
• Method of analysis = ANCOVA of the change in the primary outcome score controlling for baseline value 
of the primary outcome score  
• Intention -to-Treat Analysis using all randomized participants , corrected for missing outcome data:  
o Multiple imputation  of the ANCOVA model using the chained equations  method with 50 
imputations using the Stata Software Command:  m i 
• Minimal Clinical Important Difference (MCID) = 0.62 SD (0.5 subscore  points)  
• Sample size software: Stata Software Command: power repeated  
• Sample size = 108 total  (54 per group ) 
 
 
Sample size for the primary outcome varying the MCID  
MCID in SD units  0.3 SD  0.50 SD  0.62 SD*  1 SD  
MCID subscore units  0.24  0.4 0.5 0.8 
Total sample size  460 168 108 42 
Number per group  230 84 54 21 
* MCID between investigator -related severity and fullness/early satiety subscore range=0.62 -0.70 SD  [25] 
 
For the key secondary outcome, symptom improvement by 1 -point or more in  the PAGI -SYM GSCI total score  from 
baseline to week 4 , we determined that the total sample size of 108 participants (54 per group) gives  80% power 
to detect a n MCID  for a relative improvement ratio=1.8 (60% buspi[INVESTIGATOR_131520]. 32% (placebo based on APRON 
BESST  Protocol #  [ADDRESS_272395] Protocol -  Version 1.3  Confidential, not for distribution  40 placebo data )). We used a nominal Type 1 error of 5%, with no corrections of the Type [ADDRESS_272396] previously recruited for two t rials for the GpCRC and along with their 
experiences in their clinic research were confident that the estimated number of 18 participants per site at a rate 
of one participant per month per site was a recruitment target that could be met. 
 
9.3 POPULATIONS FOR A NALYSES  
Analysis dataset s will include:  
a. Intention -to-Treat – all randomized  participants  
b. Safety Analysis Dataset –  participants who took at least one dose of  treatment  
c. Other Datasets for Sensitivity analyses on a per -protocol basis (as needed: by [CONTACT_143885], sex, race, narcotic 
use, etc.)  
i. Complete-C ase Analysis Dataset –  subset of participants with 4 -week outcome  data  
ii. Adherence Analysis Dataset –  subset of participants who  took at least 80% of treatment  
 
9.4 STATISTICAL ANALYSES  
9.4.1  GENERAL APPROACH  
 
The primary analysis is an intention-to -treat analysis of the change in the PAGI- SYM questionnaire  
postprandial fullness/early satiety subscore over 4 -weeks of treatment. This subscore is calculated as the 
average of four items on the PAGI-SYM  questionnaire: stomach fullness, inability to finish a normal-sized 
meal, feeling excessively full after meals, and loss of appetite. The subscore average and each item score 
ranges from 0  (none) to 5 (very severe) on an ordinal scale and is treated as a continuous measure. The 
statistical model for change in postprandial fullness/early satiety at 4 -weeks will be an ANCOVA model with an 
indicator variable for treatment group adjusted for th e baseline value of the postprandial fullness/early satiety 
subscore. If a participant has missing [ADDRESS_272397] the 4 -week outcome data, but conclusions about the primary objective will be 
based on the intention -to-treat analysis. In addition, sensitivity analysis may be done using the subset of 
participants with adherence (defined as taking their treatment at least 80% of the time).  
 
 
9.4.2  ANALYSIS OF THE PRIMARY EFFICACY OUTCOME (S) 
• Intention -to-Treat (ITT) Analysis Dataset  
 
The primary outcome will be change in the PAGI-SYM questionnaire postprandial fullness/early satiety subscore 
from baseline to 4 weeks; this subscore is calculated by [CONTACT_226546] 4 PAGI -SYM items: stomach 
fullness, inability to finish a normal -sized meal, feeling excessively full after meals, and loss of appetite.  The 
subscore average and each item score ranges from 0 (none) to 5 (very severe) on an ordinal scale and is treated as 
a continuous measure. The treatment effect will be estimated usi ng an intention- to-treat (ITT) analysis of 
covariance (ANCOVA) model, regressing the change from baseline in postprandial fullness/early satiety subscore 
at 4-weeks on an indicator variable for treatment group and the baseline value of the outcome. The tre atment 
group difference in adjusted mean change will be presented, along with a two -sided 95% confidence interval, and 
a P-value.  
BESST  Protocol #  [ADDRESS_272398] Protocol -  Version 1.3  Confidential, not for distribution  41  
The confidence limits and P -value will come from the Intention-to -Treat multiple imputation ANCOVA model 
using all randomized participant s, corrected for missing data, as described in Section 9.2 above. 
  
Descriptive analyses will address the assumption of normality of the outcomes using distributional tests (Shapi[INVESTIGATOR_2152] -
Wilks) and plots (lowess smoothed histograms, boxplots ). Tests of normality of the residuals post -ANCOVA 
regression will be done. If the norma lity assumptions are not met, then sensitivity analyses using bootstrapped 
ANCOVA regression will be used to assess validity of the confidence limits and P -values.  
 
Secondary, sensitivity analyses of the primary outcome will use the ITT Dataset and include : 
• Complete  case ANCOVA, excluding participants with missing data  
• The same analysis as above comparing subset s of participants with high   vs. not high adherence  
• Repeat the Intention -to-Treat analysis adjusting for potential confounders not balanced by [CONTACT_101148] , such as use of narcotics, gastroparesis etiology, percent  gastric retention, sex, and  age.  
• Other secondary, sensitivity analysis conducted will be to model each of the four individual symptom 
scores of the PAGI -SYM questionnaire postprandial fullness/early satiety subscore using the same 
method s as above.  
• Graphs plotting the time course of mean change scores of the outcome and two -sided 95% confidence 
intervals by [CONTACT_226593] (screening, 2, 4, 6 weeks) will be done. The significance of the 
overall treatment effect of change over time will be computed from generalized estimating equations (GEE) linear  regression, modeling change as a function of treatment group, visit code indicator, baseline 
value of the outcome, and a treatment group by [CONTACT_226594].  
• Using the PRO GCSI-DD, the two items, “not able to finish a normal -sized meal” and “feeling excessively 
full after meals” will be  averaged to measure postprandial  fullness/early satiety.  The same method as 
above will be used; however, the baseline value is the average of the [ADDRESS_272399] 7 -days of treatment. The change in each 
outcome is computed as the baseline average value subtracted from the 4 -week average measure. A 
sensitivity analysis using a repeated measures method to account for within participant correlation will also be  used.  
 
 
9.4.3  ANALYSIS OF THE SECONDARY OUTCOME (S) 
 
• Analysis of secondary outcomes  are not dependent on findings of the primary endpoint  
• Intention -to-Treat (ITT) Analysis Dataset (i.e., all randomized participants)  
• Complete-Case Dataset  
 
The analyses of secondary and exploratory outcomes are not dependent on findings of the primary outcome. The 
ITT Analysis Dataset will be used for any binary efficacy outcomes, and for continuous efficacy outcomes with 10% 
or more of the participants having missing data  for the 4-week outcome. In that case, the ITT Analysis Dataset 
using multiple imputation with chained equations method modeling missing data on treatment group and 
baseline value of the outcome using 50 datasets will be don e. Otherwise, the Complete -Case dataset may be used 
to analyze the continuous secondary efficacy outcomes and all safety outcomes. Except for improvement in GCSI 
total score defined as being 1 or more points less at 4 -weeks than at baseline, and some safet y measures (adverse 
event counts), the other secondary outcomes are continuous changes from baseline at [ADDRESS_272400]  Protocol #  [ADDRESS_272401] Protocol -  Version 1.3  Confidential, not for distribution  42  
The “ main ” secondary outcome is the change in the total GCSI score. This will be analyzed as both a continuous 
change variable, and  also as the binary improvement variable using a logistic regression model regressing 
improvement on treatment group and the baseline value of the total GCSI. Relative Odds, two -sided 95% 
confidence intervals and a significance level computed using a likelihood ratio test will be reported.  
 
The analysis of secondary outcomes will use complete-case analysis of covariance (ANCOVA) models for 
continuous outcomes, regressing the change from baseline in outcome at 4 -weeks on an indicator variable for 
treatment group and the baselin e value of the outcome. The treatment group difference in adjusted mean change 
will be presented, along with a two -sided  95% confidence interval, and P -value for each secondary outcome from 
the ANCOVA model for the between -groups difference in the means. P -values will be nominal, and not be 
adjusted for the multiplicity of secondary outcomes.  
 
 
9.4.[ADDRESS_272402] during the course of 
the trial. Each adverse event will be displayed showing AE name [CONTACT_226611] v5.0 when applicable, class, 
severity  grade, random patient ID, clinic, treatment group, time since randomization, resolution status and 
physician’s assessment of relatedness to treatment. Participant-specific summary tables including any adverse 
event (yes vs no), frequency of multiple adverse events (i.e., 0, 1, 2, 3+) and highest severity  grade of adverse 
event (none, mild, moderate, severe, life -threatening) will be displayed by [CONTACT_73332] p -values 
from Fisher’s exact tests.  
 
In addition, rates of adverse events and hospi[INVESTIGATOR_226531], both by [CONTACT_226595]. Count data will be analyzed using a negative binomial model accounting for 
over -dispersion of the count data.  
 
Other safety data to be monitored include baseline levels and changes in laboratory measures, weight, and ECG results. These will be compared between treatment groups using ANCOVA models for change i n measures or 
Fisher’s Exact Tests for categorical outcomes.  
 
 
9.4.[ADDRESS_272403] deviations (continuous), medians and inter -quartile range (skewed 
continuous) or  number and percent (binary, categorical) will be reported. P -values will be presented in the 
footnotes as descriptive statistics only if reaching ≤ 0.[ADDRESS_272404] (Wilcoxon rank sum tests for comparison of the 
distribution of changes i n each group) will be used  to determine significance.  
 
 
BESST  Protocol #  [ADDRESS_272405] -hoc subgroup analysis of the primary outcome will be done by [CONTACT_226596], etiology 
(diabetic or idiopathic), gastric retention (delay or not delayed), sex, age (< 50, ≥50 yrs), adherence (80%  or more  
of dose vs <80%), narcotic use at baseline and during tr ial (vs no use), symptoms at baseline (severe/v ery severe 
vs none to moderate) , BMI group (normal/und erweight vs overweight/obese) . If available at the time of the 
primary paper analyse s, then fundic accommodation at baseline (impaired vs normal) will also be included in the 
subgroup analyses . 
 
Subgroup analyses will use the same models as used for the Intention-To -Treat ANCOVA models for the complete 
data, as described above. Difference in effects between subgroups will be assessed using the same ANCOVA models 
augmented with an interaction term for the difference in treatment effects between the subgroups; a P -value less 
than 0.01 for the interaction  term from the augmented ANCOVA will be required for statistical significance of the 
subgroup difference. If subgroup differences are found, these  will be reported and used to provide additional 
information about the effectiveness of the drug in subgroups of this participant population ; however, the primary 
result of the trial will stand regardless of any subgroup differences that may be found . 
 
 
9.4.[ADDRESS_272406] 
digital scans at the GpCRC central reso urce centers, are listed below: 
 
The first and second outcomes are ancillary: 
 
1. Changes at 4 -weeks in Fundic Accommodation (FA) using digital analyses of the GES test  images  
2. Changes and mean changes , respectively,  at 4-weeks in EGG test gastric rhythm measu res and water 
satiety:  a) clinical EGG diagnosis (normal, tachygastria, bradygastria, mixed gastric dysrhythmias; b) 
percentage time and distribution of power in normal [ADDRESS_272407] and c) total volume of  water ingested.  
 
This following outcome is exploratory since it is using the PRO daily -diary version of the  ANMS  GCSI  questionnaire 
that is not currently validated; however, these outcomes may provide sensitivity analyses on several secondary 
outcomes.  
BESST  Protocol #  [ADDRESS_272408] Protocol -  Version 1.3  Confidential, not for distribution  44  
3. Mean changes at 4 -weeks in each of the 7 items on the ANMS GCSI -DD questionnaire: nausea, 
postprandial fullness, early satiety, upper abdominal pain, epi[INVESTIGATOR_226532], epi[INVESTIGATOR_226438], 
overall symptom severity, as well as the total core symptom composite  score . The average severity scores 
from the last [ADDRESS_272409] a change between 
treatment groups; however, they may provide information on buspi[INVESTIGATOR_226533].  
 
4. Changes at 4 -weeks in each of the 15 symptom severity items measured on the PAGI -SYM instrument not 
included in secondary outcomes item 3, including retching, lower abdominal pain, lower abdominal 
discomfort, constipation, and  diarrhea  
5. Changes at 4 -weeks in each of t he 5 subscores of the Gastrointestinal Symptom Rating Scale (GSRS).  
 
[ADDRESS_272410]’s study files . 
 
[IP_ADDRESS]  CONSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO PARTICIPANTS  
 
Consent forms describing in detail the study intervention, study procedures, and risks are given to the participant and written documentation of informed consent is required prior to st arting intervention and administ ration of 
the study intervention  and procedures . The following consent materials , BESST Combined Consent –  HIPPA Adult, 
are submitted to IRBs with this BESST protocol . 
 
[IP_ADDRESS]  CONSENT PROCEDURES AND DOCUMENTATION  
 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and continues throughout the individual’s study participation. Consent forms will be Institutional Review Board (IRB) -
approved and the participan t will be asked to read and review the document. The investigator will first explain the 
research study to the participant and answer any questions that may arise. A verbal explanation will be provided 
in terms suited to the participant’s comprehension of the purposes, procedures, and potential risks of the study 
and of their rights as research participants.  
 
Participants will have the opportunity to carefully review the written consent form and ask questions prior to 
signing. The participa nts should have the opportunity to discuss the study with their family or surrogates or think 
about it prior to agreeing to participate. The participant will sign the informed consent document prior to any procedures being done specifically for the BESST study. Participants must be informed that participation is 
voluntary and that they may withdraw from the study at any time, without prejudice. A copy of the informed 
BESST  Protocol #  [ADDRESS_272411] Protocol -  Version 1.3  Confidential, not for distribution  45 consent document will be given to the participants for their records. The informed consent process will be 
conducted and documented in the source document s (including the date)  for the participant , and the form signed 
before the participant undergoes any study -specific procedures. The rights and welfare of the potential 
participants will be prot ected by [CONTACT_40749].  
To minimize in -person contact [CONTACT_226597] -19 pandemic and as 
permit ted by [CONTACT_779] -specific IRB  and/or the sIRB , participants will be offered a telephone or virtual review of the 
consent in place of the in -person review of the consent.  Signature [CONTACT_226612]’s questions about the study have been answered.  
 
10.1.2   STUDY DISCONTINUATION AND CLOSURE  
 
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. 
Written notification, documen ting the reason for study suspension or termination, will be provided by [CONTACT_224965], investigator s, funding agency, the Investigational New Drug 
(IND) sponsor  (N/A)  and regulatory authorities. If the study is prematurely terminated or suspended, the Principal 
Investigator (PI) will promptly inform study participants, the Institutional Review Board (IRB), and sponsor and will 
provide the reason(s) for the termination or suspension. Study participants will be con tacted, as applicable, and 
be informed of changes to study visit schedule.  
 
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to  participants  
• Demonstration of efficacy that would warrant  stoppi[INVESTIGATOR_007]  
• Insufficient compliance to protocol  requirements  
• Data that are not sufficiently complete and/or  evaluable  
 
Study may resume once concerns about safety, protocol compliance, and data quality are addressed, and satisfy 
the DSMB, sponsor, IRB and/or Food and Drug Administration (FDA). 
 
10.1.[ADDRESS_272412] by [CONTACT_3486], their staff, and the 
sponsor(s) and their interventions. This confidentiality is extended to cover testing of biological samples in 
addition to the clinical information relating to participants. Therefore, the study protocol, documentation, data, 
and all other information generated will be h eld in strict confidence. No information concerning the study or the 
data will be released to any unauthorized third party without prior written approval of the sponsor. 
 
All laboratory specimens, study forms, reports, and other records that are part of the study data collection materials will be identified by [CONTACT_226598]. All records will be kept in 
locked file cabinets. All electro nic records of study data will be identified by [CONTACT_226599]. Clinical 
information will not be released without written permission of the participant, except as necessary for monitoring 
by [CONTACT_1201]. Consent procedures and forms, and the communication, t ransmission and storage of participant data 
will comply with individual site IRB and NIH requirements for compliance with The Health Insurance Portability 
and Accountability Act  (HIPAA).  
 
All research activities will be conducted in as private a setting as  possible.  
 
BESST  Protocol #  [ADDRESS_272413] (IRB), regulatory agencies or pharmaceutical company supplying the study product may inspect all 
documents and records required to be maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site 
will permit access to such records.  
 
The study participant’ s contact [CONTACT_179138]. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_3488], Institutional p olicies, or sponsor requirements.  
 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be 
transmitted to and stored at the GpCRC SDRC. This will not include the participant’s contact [CONTACT_46203]. Rather, individual participants and their research data will be identified by a unique identification 
number and letter code. The study data entry and study management systems used by [CONTACT_226600], password -protected  and are encrypted . At the end of the study, all study 
databases will be de -identified and archived at the NIDDK Data Repository.  
 
Consent procedures and forms, and the communication, transmission and storage of particip ant data will comply 
with individual site IRB and NIH requirements for compliance with The Health Insurance Portability and 
Accountability Act (HIPAA).  
 
Per NIH Notice NOT-OD -17-109 (Notice of Changes to NIH Policy for Issuing Certificates of Confidentiali ty 
https://grants.nih.gov/grants/guide/notice-files/NOT -OD-17-109.html) , this research is deemed to be issued a 
Certificate through this Policy and is therefore required to protect the privacy of individuals who are subjects of 
such research in accordance with subsection 301(d) of the Public Health Service Act.  
 
This certificate protects identifiable research information from forced disclosure. It allows the investigator and others who have access to research records to refuse to disclose identifying inform ation on research participation 
in any civil, criminal, administrative, legislative, or other proceeding, whether at the federal, state, or local level. By [CONTACT_226601], Certificates of Confidentiality help achieve the research objectives and promote 
participation in studies by [CONTACT_4205][INVESTIGATOR_21783].  
 
10.1.4  FUTURE USE OF STORED SPECIMENS  AND DATA   
 
Biological specimens will be collected and stored for use as approved by [CONTACT_226602] 
(see Appendix 12.2  for blood collection schedule). Specimens to be stored include plasma and serum. Twenty mL 
of blood will be collected at the screening visit and at the week [ADDRESS_272414]  Protocol #  [ADDRESS_272415].,  
Scottsdale, AZ [ZIP_CODE]  
[PHONE_4792]  [PHONE_4793]  [PHONE_4791]  
[EMAIL_4473]  [EMAIL_4474]   [EMAIL_4471]   
 
GpCRC Executive Committee (EC)  - Consists of GpCRC co -chairpersons, SC representatives, principal 
investigator [INVESTIGATOR_226534], NIDDK program official, and NIDDK project scientist. The GpCRC EC discusses 
directions and strategic issues related to the scientific aims of the GpCRC; o rganizes and sets agenda for 
Steering Committee meetings and provides oversight of study.  
 
GpCRC Steering Committee (SC) –  Consists of the principal investigators of each of the clinical centers, the principal 
investigator [INVESTIGATOR_226534], and the NIDDK project scienti st, each of whom has one vote in any decision requiring a 
formal vote. The GpCRC SC is the major decision -making body for GpCRC , which provides oversight in  the planning and 
conduct of studies. The SC votes on a ll important decisions and approves the final database and protocol and any 
amendments or modifications of the protocol. 
 
10.1.6  SAFETY OVERSIGHT : DATA AND SAFETY MONITORING BOARD  
 
• Each participating clinical center is responsible for ensuring that local IRB requirements  for 
reporting adverse events ar e met.  
• The SDRC  staff at the Johns Hopkins Bloomberg School of Public Health follows the 
JHSPH IRB guidelines and reports the unanticipated problems or adverse events to the 
NIDDK and the DSMB.  
• The NIDDK appointed DSMB will monitor the data for safety and efficacy for ou tcomes such 
as toxicity and any other outcomes or events identified as  safety -related.  
 
Safety oversight will be under the direction of a n independent  Data and Safety Monitoring Board 
(DSMB) composed of individuals with the appropriate expertise, including gastroenterology, internal 
medicine, and statistics. Members of the DSMB are independent from the study conduct and free of 
conflict of interest.  
 
The DSMB  is appointed by [CONTACT_226603]. The DSMB is a multidisciplinary 
group with a written charge provided by [CONTACT_49010]. The DSMB reports to the NIDDK, which will 
com municate DSMB recommendations to the investigators, as appropriate. The DSMB will hold a 
meeting to approve the protocol. The DSMB will review performance and safety data. The DSMB 
may request more frequent meetings if necessary to fulfill its charge. It m ay also request additional 
safety reports on a more frequent basis. All serious adverse events are reported to the DSMB for their consideration and recommendations as they occur.  
 
The DSMB also reviews the overall progress of the trial in terms of recruitm ent and data quality and  
makes a formal recommendation to the NIDDK at the end of each scheduled meeting as to whether 
the trial should continue unmodified, continue with protocol modifications, or be stopped.  
BESST  Protocol #  [ADDRESS_272416] of the trial complies  with the currently approved protocol/amendment(s), with 
International Conference on Harmonisation Good Clinical Practice (ICH GCP), and with applicable 
regulatory requirement(s). 
• Monitoring for this study will be performed by [CONTACT_226604].  
• To ensure data quality and reduce d ata entry error, double -data entry of all data collection forms is 
required. The SDRC will incorporate into the data entry programs a series of edit checks, including range checks, logic checks (e.g., skip patterns), and consistency checks, both within a data form and across 
form s. These integral checks are designed to detect deficiencies in the data before they are entered into 
the study database, so that the deficiencies may be easily and accurately corrected. In addition, the SDRC  
will perform frequent computerized edit checks on entered data. The SDRC will also perform ongoing 
comparisons of copi[INVESTIGATOR_226535]. Such audits will help to pi[INVESTIGATOR_226536]. Any data queries identified will be flagged for action by [CONTACT_226605].  
• The data system will maintain a clear and complete audit trail of all chang es to the study databases. All 
changes to data forms will be documented appropriately on the paper form and entered into GpCRC  
BESST data system. All forms entered and/or edited in the data system will be identified by [CONTACT_226606] ( PIN)  of the operator, the network address (the “IP” address) of the 
computer being used, and the date and time of the operation. Records will not be deleted but rather 
marked as having been superseded. The SDRC will implement various procedures to en sure the quality of 
its internal operations. These will include the development and maintenance of documentation regarding 
procedures for receiving, processing, and analyzing data, and duplicated programming for selected 
procedures to check for errors in s oftware database and analysis systems.  
• Performance monitoring: The web -based data system will allow for real -time reporting of most 
recruitment and data management activities. However, additional performance reports will be generated and circulated monthly  and typi[INVESTIGATOR_226537] (SC) meeting. These reports 
include several key indicators of study performance, including counts of participants screened and randomized, of completed visits and of missing key data, of missed visits, and  statistics summarizing 
performance with respect to timeliness of data entry and response to data  queries. 
• The SC and the DSMB will conduct a formal review of the study by [CONTACT_226607]-person meeting 
twice a year and will address quality assurance  as part of their agenda. These Committees will have 
responsibility for recommending corrective actions based on the performance data. It is anticipated that the 
primary responsibility for formulating and implementing these actions will reside in the SC. P otential actions 
might include specific recommendations for training, redistribution of study resources, or possibly 
termination of support for a center.  
• Independent audits outside the SDRC will not be conducted.  
 
 
10.1.[ADDRESS_272417]  Protocol #  [ADDRESS_272418] Protocol -  Version 1.3  Confidential, not for distribution  49  
Quality control (QC) procedures will be implemented beginning with the data entry system and dat a QC checks 
that are run on the database. Any missing data or data anomalies will be communicated to the site(s) for 
clarification/resolution.  
 
Following written Standard Operating Procedures (SOPs), the GpCRC monitors will verify that the clinical trial is 
conducted and data are generated and biological specimens are collected, documented (recorded), and reported 
in compliance with the protocol, International Conference on Harmonisation Good Clinical Practice (ICH GCP), and 
applicable regulatory requiremen ts (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)).  
 
The investigational site will provide direct access to all trial related sites, source data/documents, and reports for 
the purpose of monitoring and auditing by [CONTACT_226608], and  inspection by [CONTACT_3482].  
 
 
10.1.[ADDRESS_272419]  KEEPI[INVESTIGATOR_1645]   
[IP_ADDRESS]  DATA COLLECTION AND  MANAGEMENT RESPONSIBILITIES  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site  Principal 
Investigator. The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the 
data reported.  
 
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data.  
 
Hard copi[INVESTIGATOR_226538]. Data recorded in the electronic case report form derived from 
source documents should be consi stent with the data recorded on the source documents.  
 
Clinical data (including adverse events (AEs), concomitant medications, and expected adverse   reactions data and 
clinical laboratory data) will be entered into the GpCRC database, a [ADDRESS_272420] protection and internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be 
entered di rectly from the source documents (case report forms). 
 
 
[IP_ADDRESS]  STUDY RECORDS RETENTION  
 
The NIDDK records retention policy is to maintain clinical trial records for 3 years after the granting period ends or 
the trial ends, whichever is later.  
 
10.1.10  PROTOCOL DEVIATIONS  
 
A protocol deviation is any noncompliance with the clinical trial protocol, International Conference on 
Harmonisation Good Clinical Practice (ICH GCP), or Standard Operating Procedures ( SOP) requirements. The 
noncompliance may be on the part o f either  the participant, the investigator, or the study site staff.  Because  of 
deviations, corrective actions are to be developed by [CONTACT_3483].  
 
These practices are consistent with ICH GCP: 
• 4.5 Compliance with Protocol, sections 4 .5.1, 4.5.2, and  4.5.3  
• 5.1 Quality Assurance and Quality Control, section  5.1.1 
• 5.[ADDRESS_272421]  Protocol #  [ADDRESS_272422] be sent to the reviewing IRB per local site  policies. The site investigator is 
responsible for knowing and adhering to the reviewing IRB requirements. Further details about the handling of 
protocol deviations will be included in the SOP.  
 
 
10.1.11  PUBLICATION AND DATA SHARING POLICY  
 
This study will be conducted in accordance with the following publication and data sharing policies and 
regulations:  
 
National Institutes of Hea lth (NIH) Public Access Policy ensures that the public has access to the published results 
of NIH -funded research. It requires scientists to submit final peer -reviewed journal manuscripts that arise from 
NIH funds to th e digital archive PubMed Central  upon acceptance for publication.  
 
This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH -Funded Clinical 
Trial Information and the Clinical Trials Registration and Results Information Submission rule. As  such, this trial will 
be registered at ClinicalTrials.gov, and results  and information from this trial will be submitted to ClinicalTrials.gov. 
In addition, every attempt will be made to publish results in peer - reviewed journals.  
 
Data from this study may be requested from the NIDDK Central Repository 
(https:// www.niddkrepository.org/search/study/) two years after the completion of the primary outcome. 
 
This study will not be collecting DNA specimens from  participants, so there will be no genomic data or genomic 
sequencing data from DNA to deposit in in the NIH Genomic Repository .  
 
10.1.[ADDRESS_272423]  Protocol #  [ADDRESS_272424] Aspartate Aminotransferase  
BMI Body Mass Index (kg/m2) 
BUN  Blood Urea Nitrogen  
CO2  Carbon Dioxide/ bicarbonate  
CBC Complete Blood Count  
CFR Code of Federal Regulations  
CMP  Complete Metabolic Panel  
CNS Central Nervous System  
CPGAS  Clinical Patient Grading Assessment Scale  
CPM  Cycles Per Minute  
CRF Case Report Form  
CTCAE  Common Terminology Criteria for Adverse Events  
CUNV  Chronic Unexplained Nausea and Vomitin g 
DSMB  Data and Safety Monitoring Board  
ECG Electrocardiogram  
EGG  Electrogastrogra m 
FA Fundic Accommodation  
FDA Food and Drug Administration  
GES Gastric Emptying Scintigraphy  
GCSI  Gastroparesis Cardinal Symptom Index  
GCSI -DD Gastroparesis Cardinal Symptom Index – Daily Diary  
GERD  Gastroesophageal reflux disease  
GpCRC  Gastroparesis Clinical Research Consortium  
GpR Gastroparesis Registry (study ) 
GSRS  Gastrointestinal Symptoms Rating Scale  
HADS  Hospi[INVESTIGATOR_226539] -to-Treat  
MAO I Monoamine oxidase  inhibitor  
MCID  Minimal Clinical Important Difference  
N/A Not applicable  
NIDDK  National Institute of Diabetes and Digestive Kidney Diseases  
OHRP  Office of Human Research Protections  
PAGI -QOL  Patient Assessment of  Upper Gastrointestinal Disorders -AGI Life 
PAGI -SYM  Patient Assessment of Upper Gastrointestinal Disorders Symptom  Severity Index  
PCP Primary Care Provider  
PHQ -[ADDRESS_272425]  Protocol #  [ADDRESS_272426]  Protocol #  [ADDRESS_272427] Protocol -  Version 1.3  Confidential, not for distribution  53 10.4 PROTOCOL  AMENDMENT  HISTORY  
The table below is intended to capture changes of IRB -approved versions of the protocol, including a description of the 
change and rationale. A Summary of Changes table for the current amendment is located in the Protocol Title Page.  
 
 
Version 1.2; 11 Sep 2020  Description of Change  Brief Rationale  
 
1.1 Synopsis  
Changed age range from 18 -75 to 18- 85  
Changed Total Study Duration to 96 weeks (24 months)  
Changed Recruitment to 90 weeks (22.5 months)  
Changed: Expected enrollment rate to .8 participant per month per 
clinical center (18 participants each at 6 centers)  Compliance with Inclusion across 
the Lifespan policy.  
Recruitment has been slower 
than expected. This will extend 
through May 31, 2021.  
 
1.3 Schedule of Activities  
Removed x at  screening for Clinical Patient Grading Assessment 
Scale (CPGAS)  This is only done during follow -up 
 
5.1 Inclusion Criteria  
Changed Aged 18 to 75 years at initial screening interview to 
Aged 18 to 85 years at initial screening interview  
 Compliance with Inclusion across 
the Lifespan policy.  
 
5.5.1 Recruitment  
Changed recruitment time to 22.5 months  Recruitment has been slower 
than expected. This will extend 
through May 31, 2021.  
 
8.1.6 Study Procedures  
Deleted: This analysis reads the scintigraphic images in an 
application written for MATLAB software [17].  Remove reference to software 
used as this may change.  
 
8.1.2, [IP_ADDRESS]  
Added: To minimize in -person contact [CONTACT_226609] -[ADDRESS_272428] in person at 
the study visit and after confirmation that all of the participant’s 
questions about the study have been answered.  COVID19  
 
7.2 Participant Discontinuation/Withdrawal from the Study  
Added:  The sponsor or investigator terminates the study.  
 COVID19  
 10.3 Abbreviations  
Bicarbonate; accommodation   
Corrected spelling   
11. References  
Added PMID to References  NIH format  
 
  
BESST  Protocol #  [ADDRESS_272429] Protocol -  Version 1.3  Confidential, not for distribution  54 11 REFERENCES  
1. Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the 
diagnosis and treatment of gastroparesis. Gastroenterology 2004; 127:1592-1622.  PMID:  15521026  
2. Soykan I, Sivri B, Sarosiek I, Kierna n B, McCallum RW. Demography, clinical characteristics, psychological 
and abuse profiles, treatment, and long -term follow -up of patients with gastroparesis. Dig Dis Sci 1998; 43: 
2398-2404.  PMID: 9824125  
3. Revicki  DA, Rentz AM, Dubois  D et al. Development  and validation  of a patient -assessed  gastroparesis 
symptom severity measure: the Gastroparesis Cardinal Symptom Index. APT 2003;18(1):141-50.  
PMID:12848636 
4.   Kelly KA. Gastric emptying of liquids and solids: roles of proximal and distal stomach. Am J Physiol 
1980;239:G71-6.  PMID: 6996495 
5. Azpi[INVESTIGATOR_109683] F. Control of gastric emptying by [CONTACT_226610]. Dig Dis Sci  1994;39:18S -9S. PMID: 7995208 
6. Parkman HP, Jones MP.  Tests of Gastric Neuromuscular Function.  Gastroenterology 2009;136(5):1526-
1543 PMID: 19293005  
7. Stanghellini V, Tack J. Gastroparesis: separate entity or just a part of dyspepsia? Gut. 2014;63:1972-8.  
PMID: 25260920 
8. Pasricha PJ, Colvin R, Yates K, Hasler WL, Abell TL , Ünalp -Arida A, Nguyen L, Farrugia G, Koch KL, Parkman 
HP, Snape WJ, Lee L, Tonascia J, Hamilton F and The NIDDK Gastroparesis Clinical Research Consortium (GpCRC). Clinical characteristics of patients with chronic unexplained nausea and vomiting and normal 
gastric emptying. Clin Gastroenterol Hepatol, 2011; 9: 567 -576 PMID: 21397732   PMCID:  PMC3123425
 
9. Pasricha PJ, Yates, KP, Sarosiek I., and the GpCRC. Aprepi[INVESTIGATOR_226540] d Effects on Nausea and Reduces 
Other Symptoms in Patients with Gastroparesis and Related Disorder. Gastroenterology 2018;154:65 -76 
PMID: 29111115.  PMCID:   PMC5742047  
10. Tack J, Pi[INVESTIGATOR_223671]  H, Coulie B, et al. Role  of impaired  gastric  accommodation  to a meal  in functional  
dyspepsia. Gastroenterology 1998;115:1346– 1352.  PMID: 9834261 
11. Karamanolis G, Caenepeel P, Arts J, Tack J. Determinants of symptom pattern in idiopathic severely 
delayed gastric emptying: gastric emptying rate or proximal stomach dysfunction? Gut. 2007  Jan;56(1):29-
36 PMID: 16840507.  PMCID:  PMC1856678  
12. Troncon LE, Bennett RJ, Ahluwalia NK, Thompson DG. Abnormal intragastric distribution of food during 
gastric emptying in functional dyspepsia patients. Gut 1994; 35:  327-32.  PMID: 8150341.  
PMCID:  PMC1374584  
13.  Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a 
joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear 
Medicine. Am J Gastroenterol 2008;103:753-7 63. PMID: 18028513 
14. Pi[INVESTIGATOR_223671] H, Tack J, Walrand S, Pauwels S, Geubel A. Intragastric distribution of a standardized meal in 
healt h and functional dyspepsia: correlation with specific symptoms. Neurgastroenterol Motil  
2003;15:447- 455.  PMID: 14507346  
15. Gonlachanvit S, Maurer AH, Fisher RS, Parkman HP. Regional gastric emptying abnormalities in functional 
dyspepsia and gastroesophageal reflux disease. Neurogastroenterology Motility 2006;18:894 -904.  PMID: 
[ADDRESS_272430]  Protocol #  [ADDRESS_272431] Protocol -  Version 1.3  Confidential, not for distribution  55 16. Arasu S, Parkman HP, Maurer A. Impaired Gastric Accommodation in Gastroparesis: Relationship to 
Gastroparesis Cardinal Symptom Index (GCSI) Severity Scores. Gastroenterol ogy 2014 (abstract). Poster 
presentation at 2014 DDW Meeting.  
17. Orthey  P, Yu D, Van Natta ML, Ramsey FV, Diaz JR, Bennett PA, Iagaru AH, Fragomeni RS, McCallum RW, 
Sarosiek I, Hasler WL, Farrugia G, Grover M, Koch KL, Nguyen L, Snape WJ, Abell TL, Pasric ha PJ, Tonascia J, 
Hamilton F, Parkman  HP, Maurer AH; NIH Gastroparesis Consortium. Intragastric Meal Distribution During 
Gastric Emptying Scintigraphy for Assessment of Fundic Accommodation: Correlation with Symptoms of 
Gastroparesis.  J Nucl Med. 2018 Apr;59(4):691-697.  PMID: 28970332.  PMCID:  PMC5932748  
18. Parkman  HP, Hallinan EK, Hasler WL, et al; NIDDK Gastroparesis Clinical Research Consortium (GpCRC). Early 
satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and 
water load testin g. Neurogastroenterol Motil. 2017 Apr;29(4). doi: 10.1111/nmo.[ZIP_CODE]. Epub [ADDRESS_272432] 25.  
PMID: 27781342  PMCID:  PMC5367988  
19. Youn  YUH,  Choi  EJ, Lee YH, Oshima  T, Miwa  H, Park  H. The effects  of 5-hydroxytryptamine1a  receptor  agonist, 
buspi[INVESTIGATOR_226541]. Neurogastroenterol 
Motil. 2015 Apr;27(4):532- 41. PMID: 25677141  
20. van Oudenhove L, Kindt S, Vos R, Coulie B, Tack J. Influence of buspi[INVESTIGATOR_226542]. Aliment Pharmacol Ther  2008;28:1326-1333.  PMID: 18793342 
21. Tack J, Janssen P, Masaoka T, Farré R, Van Oudenhove L. Efficacy of buspi[INVESTIGATOR_5331], a fundus -relaxing drug, in 
patient s with functional dyspepsia. Clin Gastroenterol Hepatol. 2012  Nov;10(11):1239-45. PMID 22813445:  
22. Ly HG, Weltens N, Tack J, Van Oudenhove L. Acute Anxiety and Anxiety Disorders Are Associated With 
Impaired Gastric Accommodation in Patients With Functional Dyspepsia. Clin Gastroenterol Hepatol. 2015 Sep;13(9):1584-91.  PMID: 25869636  
23. Pasricha  PJ, Yates  KP, Nguyen  L, et al. Outcomes  and Factors  Associated  With  Reduced  Symptoms  in Patients 
with Gastroparesis. Gastroenterology.  2015;149:1762-1774.  PMID: 26299414.  PMCID:  PMC4663150  
24. Rentz AM, Kahrilas P, Stanghellini V et al. Development and psychometric evaluation of the patient 
assessment of upper gastrointestinal symptom severity index (PA GI-SYM) in patients with upper 
gastrointestinal disorders. Qual Life Res  2004;13(10):1737-49.  
25. Revicki DA, Rentz AM, Dubois D, Kahrilas P, Stanghellini V, Talley NJ, Tack J.  Gastroparesis Cardinal Symptom 
Index (GCSI): Development and validation of a p atient reported assessment of severity of gastroparesis 
symptoms.  Qual Life Research 2004;13:833-844.  PMID: 15651544 
26.  Revicki DA, Camilleri M, Kuo B, Szarka LA, McCormack J, Parkman HP. Evaluating symptom outcomes in 
gastroparesis clinical trials: val idity and responsiveness of the Gastroparesis Cardinal Symptom Index-Daily 
Diary (GCSI -DD). Neurogastroenterol Motil 2012;24(5):456-63.  PMID: 15129893 
27. Hui R. Gastroparesis: Clinical evaluation of drugs for treatment: Guidance for industry. Food and Dru g 
Administration Center for Drug Evaluation and Research (CDER). July  2015.  
28. Simmons K, Parkman HP. Granisetron Transdermal System Improves Refractory Nausea and Vomiting in 
Gastroparesis. Dig Dis Sci.  2014;59:1231- 1234.  PMID: 24615549  
29. Ware JE Jr, Sherbourne CD. The MOS 36-item short -form health survey (SF -36). I. Conceptual framework and 
item selection. Med Care 1992; 30: 473-483.  PMID: [ADDRESS_272433]  Protocol #  [ADDRESS_272434] Protocol -  Version 1.3  Confidential, not for distribution  56 30. De La Loge C, Trudeau E, Marquis P, Kahrilas P, Stanghellini V, Talley NJ, Tack J, R evicki DA, Rentz AM, Dubois 
D. Cross cultural development and validation of a patient self -administered questionnaire to access quality of 
life in upper gastrointestinal disorders: the PAGI -QOL. Qual Life Res 2004; 13: 1751-1762.  PMID: 16283929.  
PMCID:  PMC1325267  
31.  Zigmond AS, Snaith RP. The hospi[INVESTIGATOR_56105]. Acta Psychiatr Scand  1983;67:361-370.  
PMID: 6880820 
32. Svedlund J, Sjodin I, Dotevall G. GSRS --a clinical rating scale for gastrointestinal symptoms in patients with 
irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988;33:129 -34. PMID: 3123181 
33. Kroenke K, Spi[INVESTIGATOR_4280], Williams JB. The PHQ -15: validity of a new measure for evaluating the severity of 
somatic symptoms. Psychosom Med 2002; 64:  258-266.  PMID: 11914441 
34. Tougas G, Eaker EY, Abell TL, et al.  Assessment of gastric emptying using a low fat meal: Establishment of 
international control values.   Am J Gastroenterol 2000;95:1456-1462.  PMID: 10894578  
35. Abell TL, Camilleri M, Donohoe K, et al.   Consensus recommendations for gastric emptying scintigraphy: a 
joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear 
Medicine.   Am J Gastroen terol 2008;103:753-763.  PMID: [ADDRESS_272435] in patients 
with dysmotility -like dyspepsia symptoms and in control subjects. J Clin Gastro  2000;31:125-9.  PMID: 
10993427  
37. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospi[INVESTIGATOR_5620]. An 
updated literature review. J Psychosom Res 2002; 52:69–77. PMID: [ADDRESS_272436]  Protocol #  [ADDRESS_272437]  Protocol #  [ADDRESS_272438] Protocol -  Version 1.3  Confidential, not for distribution  58 12.2 BLOOD COLLECTION SCHEDULE  (amounts in mL)  
 
 
 Screening 
visits   Follow -up visits  
Weeks from Randomization  mL 
Labs   RZ f2 f4 f6 Total mL  
Complete blood count (CBC)  5  . 5 5 15 
Comprehensive metabolic panel  (CMP)  2 . . 2 2 6 
Thyroid Stimulating Hormone (TSH)  2 . . . . 2 
Fasting HbA1c  5 . . . . 5 
Banking:        
Fasting plasma  [ADDRESS_272439] study visits with blood collection are fasting visits and need to be scheduled for early morning. Fasting is 
defined as nothing by [CONTACT_226580] , except for a small amount of water to take medications .  
  